

Original Chapter

Female reproductive organ cancer and the recent advances in their treatment, also AI used for cancer treatment.

Tejaswini P. Masne, Krishna R. Gupta, Milind J. Umekar

Department of Pharmaceutical Chemistry

Smt. Kishoritai Bhoyar College of Pharmacy, Kamptee, Nagpur (441001), Maharashtra, India.

Email Id- tejaswinimasne20@gmail.com

Abstract

The purpose of this chapter is to aware about the female reproductive organ related cancer and their treatment available world wide and how Artificial Intelligence useful in treatment. Cervical, endometrial, and ovarian malignancies exhibit a relatively prevalent occurrence, contrasting with the rarity characterizing other neoplasms within the spectrum of the female reproductive system. Encounters with other substances possessing well-substantiated carcinogenic attributes predominantly arise via medical interventions (such as diethylstilbestrol administration, utilization of oral contraceptives or hormone replacement therapy, exposure to X-radiation and γ -radiation), environmental influences (as observed in atomic bomb survivors), individual behavioral choices (smoking habits, application of talc-based body powder to the perineal region), or viral infections involving human immunodeficiency virus-1 (HIV1) and various strains of human papillomavirus (HPV).

Keywords: Breast cancer, Female reproductive organ cancer, vulva cancer, Artificial Intelligence, etc.

Introduction

Cancer results in an annual mortality count of approximately 459,000 within the Eastern Mediterranean Region. Over the preceding quinquennium, the Region bore witness to nearly 1.6 million incidences of cancer, thus establishing an unrelenting encumbrance characterized by profound physiological, emotional, and fiscal exigencies upon individuals, households, and communities. Annually, nearly 734,000 individuals receive a cancer diagnosis, with prognostications indicating an envisaged 50% surge in diagnoses by the year 2040. These statistics emanate from the World Health Organization's recent advocacy campaign on World Cancer Day 2023.

Cancer, a diverse array of afflictions, can initiate in virtually any bodily organ or tissue, wherein aberrant cellular proliferation transpires in an unbridled manner, transgressing customary confines to infiltrate contiguous anatomical domains, and/or disseminating to distant organs. This latter phenomenon, recognized as metastasis, substantiates a primary cause of mortalities attributed to cancer. Synonymous nomenclature for cancer encompasses neoplasms and malignant tumors. Serving as an overarching terminology for a heterogeneous cohort of ailments, cancer possesses the capacity to impact any bodily locale. Characteristic to cancer is the swift genesis of anomalous cells that surmount customary boundaries, ultimately embarking on intrusion into adjacent anatomical domains and metastasizing to remote organs—an occurrence identified as metastasis. The pervasive incidence of metastatic dissemination stands as the foremost contributor to fatalities ensuing from cancer.¹

Lung, throat, colorectal, stomach, breast, uterus/cervix, ovarian, prostate, testicular, and other cancers are only a few examples of the many types of cancer that exist worldwide. Breast cancer, uterine/cervical cancer, ovarian cancer, and other female reproductive organ cancers are discussed in this chapter. This chapter also discusses current cancer treatments and how machine learning and artificial intelligence (AI) are employed in cancer care.

Types of Female reproductive organ cancers:

- 1) Breast Cancer
- 2) Uterus / Cervix Cancer
- 3) Ovarian Cancer
- 4) Vaginal Cancer
- 5) Vulvar Cancer




Fig. no. 1- Comprehensive Overview of Female reproductive organs.

1) Breast Cancer

Breast cancer stands as the foremost prevalent malignancy affecting women on a global scale. The year 2020 bore witness to the diagnosis of 2.3 million women with breast cancer, culminating in 685,000 fatalities across the world.

As of the culmination of 2020, a cohort of 7.8 million women had survived breast cancer diagnoses within the antecedent five-year interval, underscoring its unparalleled ubiquity within the realm of oncological afflictions.

Breast cancer manifests as a pathological condition characterized by the uncontrolled proliferation of aberrant breast cells, giving rise to tumorous growths. In the absence of effective containment, these neoplastic formations have the propensity to disseminate systemically, thereby engendering potentially lethal consequences.

The nomenclature "breast cancer" pertains to neoplastic transformations originating from breast tissue, frequently arising from the luminal epithelial cells lining mammary ducts or the glandular lobules responsible for milk production. Benign, or non-invasive, variants of breast cancer entail localized growths that do not infiltrate adjacent organs. Conversely, malignant, or invasive, breast cancer exhibits an invasive predilection, infiltrating neighboring tissues and thereby posing prognostic intricacies attributed to heterogeneous clinical trajectories. Consequently, the early and precise determination of diagnosis and prognosis emerges as a critical imperative to facilitate timely therapeutic interventions, thereby augmenting patient survivability. Survivability delineations span the temporal spectrum, encompassing both short-term (less than five years) and long-term (greater than five years) durations. Prognostic paradigms offer invaluable insights to clinicians, particularly those attending to individuals with short-term survivability prospects and confronted with a multifaceted disease entity.²


Neoplastic cells exhibit a notable resemblance to the host organism's cells from which they derive, featuring analogous yet not completely identical DNA and RNA profiles. This intrinsic similarity constitutes a key rationale for their limited detection by the immune system, particularly when the latter is compromised in its vigilance and efficacy.³ Cancerous cells arise from normal cells through modifications or mutations within their DNA and/or RNA. These alterations can transpire spontaneously in accordance with the Second Law of Thermodynamics, leading to increased entropy, or they may be induced by extraneous factors including nuclear radiation, electromagnetic radiation (comprising microwaves, X-rays, Gamma-rays, Ultraviolet-rays, etc.), viral, bacterial, and fungal agents, parasitic entities (stemming from tissue inflammation or irritation), thermal influences, airborne, aquatic, and dietary chemical agents, mechanical perturbations at the cellular level, generation of free radicals, and the progression of DNA and RNA through processes such as evolution and aging. These diverse influences can engender mutations that initiate the development of cancerous states. Consequently, cancer may aptly be designated as an "Entropic Disease," signifying its association with the escalating entropy of the organism to a point where intrinsic self-correction becomes untenable. Remediation necessitates external intervention to restore the organism to a state of equilibrium with reduced entropy.⁴

Cancer pathogenesis transpires when immune surveillance mechanisms are compromised and/or cellular proliferation exceeds the immune system's capability for effective containment. The pace of DNA and RNA mutagenesis can be markedly escalated within specific contexts, encompassing deleterious environmental settings marked by factors like radiation, chemical agents, and comparable stressors. An inadequately nourishing dietary milieu contributes to an unfavorable cellular microenvironment conducive to mutational events. Individuals bearing genetic susceptibilities to mutagenic occurrences, along with those reaching an advanced age, particularly surpassing 80 years, exhibit an elevated propensity for heightened DNA and RNA mutational frequencies⁵⁻⁸.(Fig.no.2)

Clinical manifestations indicative of breast cancer encompass:

- Modification in the morphological attributes of the nipple or transformations in the integument encircling the nipple (areola).
- Discharge from the nipple characterized by sanguineous or atypical attributes.
- Presence of a nodule or substantial density within the breast tissue.
- Alteration in the chromatic presentation of the breast tissue.
- Dimpling or indentations on the cutaneous surface of the breast.
- Incidence of pain localized within the breast or nipple region.

Numerous factors contribute to the formation of breast nodules, with the majority of instances being non-malignant. Upwards of 90% of breast masses do not exhibit malignant attributes. Non-malignant anomalies encompass a spectrum of benign growths, including fibroadenomas and cysts, alongside inflammatory processes. Nevertheless, if any of the aforementioned symptoms are experienced, prompt medical attention is advised without delay.



Created in BioRender.com bito

Fig. no.2- Comprehensive Overview of Breast cancer.

1.1. Surgery

The prevailing methodologies for breast surgical interventions encompass two primary approaches: mastectomy, entailing the complete removal of the breast, often succeeded by subsequent breast reconstruction; and lumpectomy, involving the surgical resection of the breast tumor alongside a periphery of adjacent healthy tissue. In the context of lumpectomy, the desired margin outcome is articulated as "no ink on tumor," signifying the absence of residual neoplastic cells at the boundary of the excised tissue.⁹ Research findings indicate that there exists a comparable equivalence in terms of both relapse-free survival and overall survival between the therapeutic strategies of total mastectomy and lumpectomy followed by irradiation.¹⁰ Exclusions from the consideration of breast-conserving surgery encompass situations such as the existence of widespread microcalcifications displaying suspicious or malignancy-associated attributes, instances where the malady cannot be encompassed through localized excision while concurrently achieving an acceptable aesthetic outcome, and the presence of an ataxia-telangiectasia mutated (ATM) mutation characterized by biallelic inactivation.¹¹ The surgical procedure involving the extraction of axillary lymph nodes serves a dual purpose: it serves as an evaluative measure to ascertain the extent of malignant cell dissemination, and concurrently holds therapeutic significance. Axillary lymph node dissection (ALND), for instance, has the potential to enhance survival rates by eliminating residual tumor cells. Historically, ALND stood as the benchmark for eradicating positive lymph nodes. Nevertheless, findings from clinical trials have unveiled that the sentinel lymph node biopsy (SLNB) yields comparable outcomes to ALND in terms of both disease-free survival (DFS) and overall survival (OS).¹² Subsequent clinical investigations have revealed that a universal requirement for axillary lymph node dissection (ALND) is not imperative for all patients presenting with positive lymph nodes. Furthermore, a significant proportion of patients who undergo radiation therapy and systemic treatment subsequent to sentinel lymph node biopsy (SLNB) exhibit negative lymph nodes, as these therapeutic modalities prove sufficiently effective in eradicating residual neoplastic cells.¹¹⁻¹²

1.2. Radiotherapy

Radiation therapy has been employed as a modality for cancer treatment ever since the discovery of X-rays by Wilhelm Röntgen in 1895.¹² Elevated-energy radiation emissions are administered to either the complete mammary gland or a specific segment thereof (following breast-conserving surgery), the thoracic wall (subsequent to mastectomy), and regional lymph nodes.¹³ A comprehensive meta-analysis demonstrated that post-conservative surgery radiation therapy provides enhanced advantages for patients diagnosed with higher-risk breast cancer, whereas individuals with diminutive, low-grade tumors could potentially omit radiation therapy.¹⁴ In individuals with positive lymph nodes, the administration of post-mastectomy radiation directed at the thoracic wall is linked to a reduced risk of recurrence and breast cancer (BC) mortality in contrast to patients presenting with negative lymph nodes.¹⁵ After mastectomy, an adjunctive radiation boost within the framework of regional node radiation treatment can be integrated for patients characterized by an elevated susceptibility to recurrence.¹⁶ The supplementary radiation boost applied to regional nodes subsequent to mastectomy has been correlated with enhanced disease-free survival (DFS), although it also accompanies an elevation in radiation-induced adverse effects, encompassing conditions like pneumonitis and lymphedema. Radiotherapy can be simultaneously administered in conjunction with tailored therapeutic interventions, encompassing anti-HER2 therapy or endocrine therapy.¹⁷ Given that cardiotoxicity stands as a principal sequelae of radiotherapy, it becomes imperative to mitigate the extent of heart and lung exposure.¹⁸ Supplementary methodologies can be harnessed to curtail radiation exposure to cardiac, pulmonary, and healthy tissues, including employing prone positioning, implementing respiratory control strategies, and leveraging intensity-modulated radiotherapy techniques.¹⁹ Radiation therapy resistance can be present in advanced invasive BC.²⁰ Lack of oxygen in the tumor's microenvironment causes hypoxia, which increases cell growth, apoptosis resistance, and radiation resistance.²¹ The protein HIF-1 (hypoxia-inducible factor 1 alpha) is a key component of this resistance.²² In fact, HIF-1 overexpression contributes to

the maintenance of hypoxia by enabling tumoral cells to persist in a hypoxic milieu, which is brought on by low oxygen levels in the microenvironment.²³⁻²⁵ Radiation therapy resistance may also be attributed to cancer stem cells (CSC)²⁶. CSC are capable of self-renewal and the initiation of distinct subpopulations of progeny, and a hypoxic milieu is perfect for CSC survival and growth.²⁷⁻²⁸

Radiation therapy constitutes a therapeutic approach applicable across all breast cancer (BC) subtypes; however, its significance is heightened within the context of triple-negative breast cancer (TNBC) due to the absence of tailored therapeutic interventions for this particular subtype. Evidence underscores that radiotherapy yields advantageous outcomes for TNBC patients, both following breast-conserving surgery and mastectomy procedures²⁹⁻³⁰.

1.3. Chemotherapy

Breast cancer (BC) chemotherapy encompasses diverse classes of cytotoxic agents, encompassing alkylating agents, antimetabolites, and tubulin inhibitors³¹. Within the alkylating agent category, cyclophosphamide, a nitrogen mustard derivative, engenders DNA strand breaks through its mechanism of action³². Anthracyclines (doxorubicin, daunorubicin, epirubicin, and idarubicin) exert their effects by intercalating with DNA, thereby impeding macromolecular biosynthesis³³. Taxanes, inclusive of docetaxel and paclitaxel, bind to microtubules, arresting their disassembly, thereby inducing cell cycle arrest and apoptotic cell demise³⁴.

The administration of chemotherapy can be undertaken in the neoadjuvant or adjuvant context, as well as in the context of managing metastatic breast cancer.

1.3.1. Neo-adjuvant Chemotherapy (NAC)

Neo-adjuvant chemotherapy initially found its application in the management of non-metastatic yet inoperable breast cancer cases, pertaining to tumors deemed inaccessible³⁵. Subsequently, its implementation extended to operable tumor scenarios, aiming to facilitate breast conservation.

Evidentiary investigations have underscored the parity in efficacy between pre-surgical and post-surgical chemotherapy administration³⁶. The NSABP-B-18 trial scrutinized the impacts of administering doxorubicin and cyclophosphamide either postoperatively or preoperatively³⁷⁻³⁹. This trial's findings revealed that neoadjuvant chemotherapy (NAC) engenders a reduction in the incidence of axillary metastases within patients afflicted by node-negative breast cancer⁴⁰.

Certain patients exhibit an absence of achieving a pathological complete response even following the completion of an entire regimen of neoadjuvant chemotherapy (NAC). Regrettably, there is an absence of unanimity concerning the subsequent treatment approach for individuals who retain residual disease post-surgery⁴¹⁻⁴². The specific breast cancer (BC) subtype significantly influences the response to neoadjuvant chemotherapy. Notably, triple-negative breast cancer (TNBC) and human epidermal growth factor receptor 2-positive (HER2+) BC tend to manifest heightened sensitivity to chemotherapy. Consequently, NAC emerges as a judicious strategy to optimize the attainment of a pathological complete response within these particular BC subtypes.⁴³

1.3.2. Adjuvant Chemotherapy

Adjuvant chemotherapy is prescribed for patients with breast cancer (BC) who present lymph node metastases or exhibit a pronounced susceptibility to recurrence, thereby constituting a high-risk cohort⁴⁴. The conventional chemotherapy regimen involves the incorporation of an anthracycline in combination with a taxane. Prevalent among such regimens is the utilization of cyclophosphamide and doxorubicin administered over a span of four cycles, followed by a subsequent four-cycle administration of paclitaxel. Subsequently, patients receive the earlier amalgamation of therapeutic agents, succeeded by either a 12-week course of weekly paclitaxel or four cycles of docetaxel administered every three weeks.⁴⁵⁻⁴⁶

Similar to neoadjuvant therapy, individuals diagnosed with hormone receptor-negative (HR-negative) breast cancer (BC) accrue greater advantages from adjuvant therapy in terms of mitigating the risk of BC recurrence and associated mortality, in comparison to their hormone receptor-positive (HR+) counterparts.⁴⁷ Nevertheless, in the case of patients diagnosed with hormone receptor-positive (HR+) breast cancer (BC) that lacks lymph node involvement and exhibits an elevated Oncotype recurrence score (≥ 31), computed from the expression levels of 16 genes associated with BC and 5 reference genes, the implementation of adjuvant chemotherapy contributes to a reduction in the probability of disease recurrence.⁴⁸ The TAILORx clinical study shown that chemotherapy alone is ineffective for HR+ BC patients with a low Oncotype recurrence score.⁴⁹

Tailored to the specific molecular subtype of breast cancer (BC), the incorporation of chemotherapy can be complemented with targeted therapeutic interventions. In the context of hormone receptor-positive (HR+) BC, patients are recommended to undergo endocrine therapy subsequent to the completion of chemotherapy, whereas individuals

diagnosed with HER2+ BC are advised to receive a combination of trastuzumab and chemotherapy.⁵⁰ A taxane and anthracycline combination is used as the first line of treatment for TNBC patients.⁵¹

A prominent limitation associated with chemotherapy lies in its propensity to induce adverse effects. The initial phase of adverse events (spanning 0–6 months of treatment) encompasses fatigue, alopecia, cytopenia (characterized by diminished normal blood cell counts), myalgia, neurocognitive impairments, and chemotherapy-induced peripheral neuropathy. In the subsequent chronic or prolonged interval (exceeding 6 months of treatment), enduring side effects encompass cardiomyopathy, secondary malignancies, premature onset of menopause, infertility, and psychosocial ramifications.⁵²

Taxanes, anthracyclines, and cyclophosphamide are the main components of chemotherapy, as was previously described in this article. Patients with BC may develop resistance to any of these compounds.⁵³

Overexpression of p-glycoprotein, an ATP-binding cassette (ABC) family member that confers resistance to anthracycline and taxanes, is one method of resistance.⁵⁴ When overexpressed, the ABC family member breast cancer resistance protein (BCRP) causes resistance to anthracyclines but not to taxanes.⁵⁵ Taxane resistance can also result from microtubule changes. Paclitaxel resistance is brought on by α -tubulin III overexpression.⁵⁶ Additionally, changes in microtubule dynamics and increased taxane resistance are caused by mutations in microtubule-associated proteins (MAPs).⁵⁷ A multitude of enzymes are recognized participants in the detoxification process of cyclophosphamide, consequently contributing to the development of resistance to this agent. For instance, the upregulation of aldehyde dehydrogenase facilitates the detoxification of aldophosphamide, a variant of cyclophosphamide. Additionally, mutations occurring in glutathione S-transferases, which are instrumental in mediating conjugation reactions during drug metabolism, can likewise exert an impact on the detoxification of cyclophosphamide.⁵⁸⁻⁵⁹

Surgical intervention, radiotherapy, and chemotherapy collectively constitute complementary modalities within the therapeutic framework for breast cancer (BC) patients. Nonetheless, these approaches are not universally efficacious across all BC molecular subtypes, given their variable responsiveness to radiotherapy and chemotherapy.

Consequently, personalized therapeutic strategies emerge as imperative components within the paradigm of BC treatment.

Mitigate your susceptibility to breast cancer through the adoption of improved behavioral decisions, encompassing the following actions:

- Sustaining a favorable body weight
- Engaging in regular physical activity
- Refraining from detrimental alcohol consumption
- Opting for breastfeeding
- Abandoning tobacco consumption and evading exposure to tobacco smoke
- Steering clear of extended hormone utilization
- Circumventing excessive exposure to radiation.

Artificial intelligence (AI) is anticipated to assume a central role in forthcoming advancements within medical domains primarily reliant on technology and imaging, such as radiation oncology (RO), while concurrently preserving the roles and human dimensions of the healthcare practitioners involved. Operating as a subset of machine learning (ML), deep learning (DL) relies on artificial neural networks, thereby enabling the automatic extraction of hierarchical attributes from diverse source data. These attributes are subsequently harnessed across diverse clinical applications, encompassing imaging, volumetric delineation, and treatment strategizing.⁶⁰⁻⁷¹ The integration of artificial intelligence (AI) and deep learning (DL) methodologies is progressively becoming a prominent feature within the ambit of breast cancer diagnosis, encompassing domains such as imaging and pathological assessment.⁷²⁻⁷⁹ Information derived from diverse origins, encompassing mammography, ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), pathology analyses, surgical documentation, radiation therapy (RT) records, and follow-up imaging, is subjected to bioinformatics techniques. These methods serve to prognosticate outcomes and steer multidisciplinary therapeutic interventions, among them radiation therapy (RT). Risk evaluation algorithms, leveraging data pertaining to geometric, temporal, and spatial fluctuations in recurrence propensities, alongside insights into toxicity and aesthetic results, are poised for integration. Their incorporation will guide treatment planning algorithms, optimizing therapeutic selections and, consequently, enhancing patient outcomes.⁸⁰⁻⁸⁶

2)Uterus / Cervix Cancer

The uterus serves as the anatomical locus where fetal development occurs during pregnancy. Structurally, the uterus resembles a hollow, inverted pear in terms of its size and configuration.⁸⁷⁻⁸⁹ The uterus constitutes an integral component of the female reproductive system, situated within the pelvic cavity's lower region, positioned amidst the

bladder and the rectum. Anatomically, it establishes a connection with the vagina through the cervix. Adjacent to the uterus on bilateral facets are the ovaries, housing ova (eggs).⁹⁰⁻⁹³ The ovaries establish connectivity with the uterus through the fallopian tubes. In certain individuals, the uterus might not maintain its characteristic position in the intermediate flexion and motor state. Three prevalent modes of deviation encompass:

- Excessive anteversion
- Crossed and retroverted
- Retroflexed and retroverted

These anomalous configurations do not inherently precipitate any inherent medical issues. Nevertheless, the retroverted uterus assumes a position immediately above the vaginal canal.(Fig.no.3) Consequently, instances involving heightened intra-abdominal pressure raise the likelihood of the uterus descending into the vaginal canal⁹⁴. Uterine prolapse, particularly prevalent in individuals with a history of pelvic floor trauma, can engender a spectrum of difficulties for women.⁹⁵⁻⁹⁷.




Fig. no. 3- Comprehensive Overview of Uterus cancer.

Cervical cancer emerges as a consequence of aberrant and accelerated proliferation of cervical cells. The cervix, situated between the vagina and the uterus within the female anatomy, serves as the anatomical context for this neoplastic process. Neglecting timely diagnosis and intervention for this malignancy unquestionably poses a substantial risk to an individual's life.⁹⁸⁻¹⁰¹ Historically, cervical cancer held the position of the primary contributor to mortality among American women, yet presently it stands as the most preventable malignancy in the female population. The integration of routine Pap smear examinations, human papillomavirus (HPV) vaccinations, and HPV testing has significantly streamlined the preventive measures against cervical cancer. Acquiring knowledge about the indicative manifestations of cervical cancer enhances the prospects of early detection and prompt therapeutic intervention.(Fig.no.3)




Fig.no. 4- Comprehensive Overview of stages of Cervical Cancer.

The cancer's stage furnishes crucial insights into its dimensions and extent of dissemination. In this context, "type" denotes the cellular origin of the cancer. Meanwhile, "grade" pertains to the extent of cellular abnormality observable through microscopic examination. Your medical practitioner will amalgamate this comprehensive information to inform the determination of your requisite treatment regimen.¹⁰²

- **Stage 1** - In this phase, the cancer remains localized solely within the cervix. The primary mode of treatment is surgical intervention, supplemented by chemotherapy in certain cases.(Fig.no.4)¹⁰³
- **Stage 2**- In this progression, the cancer has extended beyond the confines of the cervix, infiltrating the adjacent tissues. The primary therapeutic modalities encompass a synergistic approach involving chemotherapy and radiation therapy, occasionally complemented by surgical intervention.(Fig.no.4)¹⁰⁴
- **Stage 3**- In this phase, the cancer has disseminated to neighboring anatomical structures or lymph nodes located within the pelvic or abdominal region. The standard therapeutic regimen typically involves a synergistic utilization of chemotherapy and radiotherapy (chemoradiotherapy).(Fig.no.4)¹⁰⁵
- **Stage 4** - This designation indicates that the cancer has metastasized to encompass the bladder, rectum, or regions beyond.(Fig.no.4)¹⁰⁶

The primary therapeutic approaches encompass chemotherapy utilizing cancer-specific agents, surgical intervention, radiotherapy, or symptom management.

2.1. Surgery¹⁰⁷ – Surgical intervention is the principal course of action for addressing cancer at the initial stage. If diagnosed with stage 1 cancer, a hysterectomy may be recommended. Alongside the removal of the uterus, a procedure termed bilateral salpingo-oophorectomy (BSO) entails the excision of the fallopian tubes and ovaries. The surgical procedure may additionally encompass the retrieval of specimens from lymph nodes in the pelvic and abdominal regions, as well as adjacent anatomical structures. These specimens are subjected to laboratory analysis to ascertain the extent of cancer dissemination.

The prevailing technique for performing a hysterectomy often involves a substantial incision located at the abdomen's midpoint, facilitating the removal of the uterus. Alternatively, circumstances may allow for the utilization of the laparoscopic hysterectomy method, commonly referred to as the "keyhole" approach. In this approach, minor incisions are made in the body to facilitate the application of a specialized instrument called a laparoscope, along with other surgical tools. This method allows the surgeon to visually access the internal body structures and effect the removal of the uterus via the vaginal route, with only minimal incisions being made.

- Discharge from the hospital is typically anticipated within a span of three to five days. If the laparoscopic surgery method is employed, this duration may be abbreviated. However, a convalescence period spanning several weeks will be requisite to attain complete recovery.
 - Following the surgical intervention, prompt ambulation is imperative. Engaging in this activity holds considerable significance; even if confined to bed, adhering to a regimen of regular leg movements is crucial to enhance circulation and avert the formation of blood clots within the body. To preclude potential complications, your healthcare provider, whether a nurse or physiotherapist, will provide guidance on specific exercises.
 - Subsequent to your hospital discharge and return to your residence, undertaking exercises aimed at bolstering your muscular strength and overall physical fitness is essential.
- Consult your physician or physical therapist to determine the most suitable exercises for your condition.

For cases of stage 2 or 3 uterine cancer involving the extension of malignancy to the cervix or pelvic lymph nodes, a comprehensive or radical hysterectomy may be indicated. This surgical intervention entails the removal of additional portions of the cervix, the upper vaginal segment, and the lymph nodes situated within the pelvic area. To mitigate the likelihood of cancer recurrence, adjunctive treatment such as radiation therapy or chemotherapy could be prescribed.

In instances of advanced uterine cancer corresponding to stage 4, debulking surgery may be considered. This surgical procedure is oriented towards the maximal eradication of cancerous tissues from the body. While this surgery does not encompass curative intent, it can potentially ameliorate certain manifestations of the malignancy. Your medical practitioner will engage in a discussion with you to ascertain the appropriateness of debulking surgery in your case.

2.2. Radiation therapy¹⁰⁸ – Radiation therapy for uterine cancer is indicated when the treatment team determines a heightened likelihood of cancer recurrence. Additionally, in situations where surgical intervention is not feasible, radiation therapy serves to impede the progression and dissemination of the malignancy. Within the realm of uterine cancer treatment, two distinct models of radiation therapy are employed:

➤ Internal radiation therapy (brachytherapy) - This involves the insertion of a plastic tube into the uterine cavity, facilitating the delivery of therapeutic radiation directly to the uterus through this conduit.

➤ External radiation therapy - Employing specialized equipment, radiation is externally directed to the pelvic region. Typically, a regimen of outpatient external beam radiation therapy, administered five days a week with a weekend respite, spans a treatment time of five minutes per session. The entire radiation therapy course may extend for approximately four weeks, contingent upon the specific stage and location of the uterine cancer. Some individuals receive concurrent internal radiation therapy (brachytherapy) alongside external radiation therapy. Brachytherapy is categorized into low, medium, and high doses, with the rate of radiation delivery determining the duration the device remains within the body. Hospital presence is required during brachytherapy sessions, during which your physician will furnish comprehensive elucidations.

The administration of radiation therapy is accompanied by potential side effects. Skin redness and tenderness may manifest in the treatment area. Hair loss can also result from radiation therapy. Pelvic radiation therapy has the potential to impact bowel function, causing symptoms like nausea and diarrhea. As treatment progresses, severe fatigue might ensue. While numerous of these side effects tend to abate post-treatment, approximately 5% of women contend with lingering treatment-related complications such as persistent diarrhea and intestinal bleeding.

2.3. Chemotherapy¹⁰⁹⁻¹¹¹- Chemotherapy for uterine cancer becomes a consideration in cases of stage 3 or 4 malignancies. The deployment of chemotherapy can encompass both preventive and palliative objectives. In the context of post-surgical interventions, chemotherapy may be employed to forestall cancer recurrence. In the context of more advanced cancers, chemotherapy seeks to curtail cancer dissemination and alleviate symptomatic manifestations. The administration of chemotherapy primarily entails intravenous injection of medications. Typically, you can return home on the same day after receiving chemotherapy, although occasionally a brief hospital stay may be warranted. Chemotherapy is often structured in alternating cycles of treatment and recovery intervals, facilitating the body's recuperation.

3) Ovarian Cancer

Epithelial ovarian cancer typically presents in advanced stages and stands as the foremost contributor to mortality among gynecological cancers. The management of this condition demands proficient interdisciplinary care. While endeavors for population-based screening have yielded limited efficacy, novel strategies utilizing molecular genomics are being developed for early detection and preventive interventions. Initial therapeutic approaches encompass surgical intervention followed by adjuvant therapies.(Fig.no.5)¹¹²

Epithelial ovarian cancer encompasses distinct histological subtypes, each characterized by unique genomic attributes. This distinction enhances the precision and efficacy of treatment strategies, allowing for the identification of response predictors such as mutations in breast cancer susceptibility genes BRCA1 and BRCA2, as well as homologous recombination deficiency that influence the efficacy of DNA damage response pathway inhibitors or confer resistance (e.g., cyclin E1). The rapid evolution of techniques for assessing genomic alterations in both tumor tissue and peripheral blood facilitates the evaluation of treatment sensitivity and the emergence of therapeutic resistance. These methods hold the potential to serve as accurate indicators of residual disease.(Fig.no.5)¹¹³⁻¹¹⁴

Regrettably, recurrence of epithelial ovarian cancer commonly defies curative interventions. During this phase, the focus shifts towards enhancing patient symptom management and maintaining quality of life. Approaches for recurrence

necessitate patient-centric design, integrating meaningful measures of therapeutic benefit. The formulation of evidence-based treatment guidelines for distinct subgroups is imperative, demanding collaborative international efforts in conducting clinical trials through academic research consortia like the Gynecologic Cancer Intergroup.¹¹⁵⁻¹¹⁷




Fig. no. 5- Comprehensive Overview of Ovarian Cancer.

Standard Treatment for Ovarian Cancer

The established therapeutic approach for ovarian cancer entails maximal cytoreductive surgical debulking followed by platinum-based chemotherapy. Surgical intervention serves the dual purpose of confirming the diagnosis and staging the disease. An essential endeavor is to delineate the tumor's histological type, which includes accurate grading.¹¹⁸ The prevailing high-grade/low-grade scale is universally applied, with the exception of endometrioid ovarian cancer that employs a three-grade scale (G1, G2, or G3).¹¹⁹ The staging assessment in surgical-pathologic terms should adhere to the existing recommendations of the International Federation of Gynecology and Obstetrics (FIGO).¹²⁰

The Gynaecologic Oncology Group (GOG) previously defined optimal cytoreduction as residual tumor nodules measuring 1 cm or less in maximum diameter. However, comprehensive multivariate analyses have demonstrated enhanced progression-free and overall survival in patients who underwent complete resection compared to those achieving so-called optimal (between 0.1 and 1 cm) and suboptimal cytoreduction ($p < 0.0001$).¹²¹ Consequently, the 2017 European Society of Gynaecological Oncology (ESGO) ovarian cancer surgery guidelines have underscored the goal of frontline surgery to achieve complete resection of macroscopic disease residuals (complete cytoreduction).¹²¹

Following surgery, patients receive intravenous platinum/taxane regimens administered every 21 days for a total of six cycles (first-line chemotherapy). Patients with stage IA/IB and G1/G2 tumors may have the option to omit chemotherapy.¹²⁰ In cases of advanced stages (III/IV), complete cytoreduction is often unattainable, frequently due to small bowel mesentery involvement and liver hilum lesions. Inoperable lesions or those associated with poor performance status are addressed with induction (neoadjuvant) chemotherapy as the initial step. After three cycles of chemotherapy, if treatment response is evident, interval debulking surgery (IDS) can be performed, followed by continuation of chemotherapy for up to six cycles.¹²⁰⁻¹²¹

New approaches to the first-line treatment

Primary debulking surgery (PDS) followed by chemotherapy has emerged as the established treatment approach for advanced epithelial ovarian cancer (EOC) since the 1980s, although substantiating randomized trials at initial stages are limited in delineating its authentic benefits. The absence of residual tumor (R0) subsequent to PDS stands as the paramount prognostic determinant for patient survival. Two randomized clinical trials comparing PDS and chemotherapy to neoadjuvant chemotherapy (NACT) pursued by interval debulking surgery (IDS) have demonstrated comparable survival outcomes with minimal operative complications in cases where NACT and IDS were implemented. Criticism has been directed towards both trials due to their reduced R0 rates and modest survival outcomes.¹²²⁻¹²³

Nonetheless, it's pertinent to acknowledge that the majority of patients encompassed an advanced stage of disease classified as stage IIIC or IV. To contribute to this discourse, the ongoing TRUST trial (NCT02828618) is investigating NACT versus PDS within specific centers with R0 rates exceeding 50%, with outcomes anticipated in forthcoming years. The decision-making process between PDS and chemotherapy versus NACT and IDS remains contentious. Further exploration is warranted to refine the patient selection criteria for PDS or NACT, encompassing enhanced and validated imaging methodologies or laparoscopic scoring systems, alongside predictive algorithms for operative morbidity prognosis.¹²¹

4) Vulva Cancer

As per the Surveillance, Epidemiology, and End Results (SEER) Database, vulvar cancer constitutes approximately 4% of all malignancies affecting the female genital tract, positioning it as a rare gynecologic malignancy.¹²² The International Agency for Research on Cancer (IARC) approximates that around 45,000 new cases of vulvar cancer are diagnosed annually, with 50.1% occurring in high-income countries.¹²³ This malignancy leads to approximately 17,000 deaths each year, primarily concentrated in high-income nations (40.8%)¹²⁴. Squamous cell carcinoma (SCC) accounts for approximately 90% of vulvar cancers¹²⁵, while less common histologic subtypes encompass basal cell carcinoma, verrucous carcinoma, Bartholin's gland adenocarcinoma, extramammary Paget's disease, and vulvar melanoma.¹²⁶(Fig.no.6)

Historically, vulvar SCC has been associated with older postmenopausal women and linked to conditions such as lichen sclerosus and other vulvar inflammatory epithelial disorders that may correlate with differentiated vulvar intraepithelial neoplasia¹²⁷. Although the median age of diagnosis stands at 69 years¹²², recent evidence reveals a rising incidence of vulvar SCC among young women on a global scale.¹²⁸ This surge is attributed to the persistence of high-risk human papillomavirus (HPV) infection, leading to an upsurge in HPV-associated high-grade vulvar squamous intraepithelial lesions. Consequently, it is estimated that approximately 45% of all vulvar SCC cases are attributable to HPV infection¹²⁸⁻¹²⁹.

Beyond HPV infection, a confluence of risk factors contributes to the elevated rates of vulvar SCC, encompassing factors such as ethnicity, smoking, vulvar inflammatory conditions, and prevalence of human immunodeficiency virus (HIV) infection.¹²⁸⁻¹²⁹


4.1. Prevention

4.1.1. Vaccination for Primary Prevention

Persistent infection by human papillomavirus (HPV), particularly type 16, has been linked to the development of high-grade squamous intraepithelial lesions (HSIL) and vulvar squamous cell carcinoma (SCC).¹³⁰⁻¹³¹ Following the implementation of HPV vaccines as a primary preventive strategy for cervical cancer, extensive investigations have been conducted to ascertain the vaccine's efficacy against non-cervical neoplasms within the female genital region associated with HPV infection.¹³¹⁻¹³⁷ These studies have established that HPV vaccination serves as an effective preventive measure against vulvar cancer, signifying a promising prospect for reducing its incidence in the future. It is projected that these vaccines could prevent approximately 70% of vulvar cancer cases attributed to HPV infection.¹³¹⁻¹³⁷

4.1.2. Screening for Secondary Prevention

Currently, there is a lack of evidence regarding specific screening tests for vulvar cancer. However, individuals with lichen sclerosus, an inflammatory condition with an unknown etiology, likely autoimmune in nature, should undertake self-examinations to identify any suspicious lesions.¹³⁷⁻¹³⁸ Furthermore, women diagnosed with intraepithelial lesions of the cervix, vagina, or anus should undergo vulvar inspections as part of their colposcopic follow-up assessments.¹³⁸



Created in BioRender.com bito

Fig.no.6- Comprehensive Overview of Vulva cancer

4.2. Staging of Vulvar Cancer

The staging of vulvar cancer adheres to the International Federation of Gynecology and Obstetrics (FIGO) guidelines (Table 1), which are generally applicable to most vulvar neoplasms, with the exception of vulvar melanoma. Since 1988, surgical staging has been employed for vulvar cancer, and the definitive diagnosis is established through comprehensive histopathological assessment of the surgical specimen, encompassing both vulva and lymph nodes.¹³⁹

Table 1. FIGO Staging of Vulvar Carcinoma¹³⁹

Stage	Description
I	Tumor confined to the vulva
IA	Tumor size ≤ 2 cm and stromal invasion ≤ 1 mm [#]
IB	Tumor size > 2 cm or stromal invasion > 1 mm [*]
II	Tumor of any size with extension to lower one-third of the urethra, lower one-third of the vagina, lower one-third of the anus with negative nodes
III	Tumor of any size with extension to the upper part of adjacent perineal structures, or with any number of non-fixed, non-ulcerated lymph nodes
IIIA	Tumor of any size with disease extension to the upper two-thirds of the urethra, upper two-thirds of the vagina, bladder mucosa, rectal mucosa, or regional lymph node metastases ≤ 5 mm
IIIB	Regional b lymph node metastases > 5 mm
IIIC	Regional b lymph node metastases with extracapsular spread
IV	Tumors of any size fixed to bone, or fixed, ulcerated lymph node metastases, or distant metastases
IVA	Disease fixed to pelvic bone or fixed or ulcerated regional b lymph node metastases
IVB	Distant metastases

[#]Depth of invasion is measured from the basement membrane of the deepest, adjacent, dysplastic, tumor-free rete ridge (or nearest dysplastic rete peg) to the deepest point of invasion. ^{*} Regional refers to inguinal and femoral lymph nodes.

Before initiating surgical treatment, a pelvic examination with vulva, vagina, and cervix colposcopy, along with cervical cytology, is essential. This evaluation serves to exclude other HPV-related pre-invasive lesions or cancers. HPV testing may also be recommended. Furthermore, comprehensive blood tests, biochemical assessments, and HIV testing are warranted. In cases of concern, radiological investigations such as chest X-ray, MRI, and PET/CT scans of the pelvis

and groin regions may facilitate lymph node assessment and aid in the planning of subsequent surgical interventions.¹⁴⁰⁻¹⁴⁵

4.3. Treatment

4.3.1. Surgical Management

Surgical interventions for vulvar cancer necessitate individualized approaches to ensure maximal oncological efficacy while preserving conservativeness.¹⁴¹⁻¹⁴³ The consideration of surgical options mandates a separate analysis of primary lesion and groin lymph node management to optimize curative potential and mitigate treatment-related morbidity.¹⁴²⁻¹⁴⁵

4.3.1.1. Microinvasive (Stage IA)

Microinvasive vulvar carcinoma, classified as stage IA, entails lesions with diameters of 2 cm or less and invasion depths not exceeding 1 mm. The invasion depth is determined from the epithelium–stromal junction of the nearest dysplastic, tumor-free superficial dermal papilla to the deepest point of invasion.¹⁴²⁻¹⁴⁵ Such lesions warrant wide, radical local excision, and inguinal lymph node evaluation is dispensable.¹⁴⁵

4.3.1.2. Early-Stage

Early-stage vulvar cancers are confined to the vulva without suspicious lymph nodes detected through clinical examination or cross-sectional radiological assessments.¹⁴⁶ In the mid-20th century, radical vulvectomy, encompassing bilateral pelvic and inguinofemoral lymphadenectomy, was employed for early-stage patients; however, its survival rate at 5 years was 75%.¹⁴⁷⁻¹⁴⁸ The adoption of radical vulvectomy on lesions up to 2 cm in diameter was questioned approximately four decades ago due to significant post-surgical complications such as infection, wound dehiscence, lymphedema, and psychosexual disorders.¹⁴⁷⁻¹⁴⁸ Radical vulvectomy's relative conservatism to prevent local recurrence is balanced against the concept of a cancerization field.¹⁴⁹ Currently, the preferred treatment for early-stage vulvar cancer is wide and radical local tumor excision,¹⁵⁰ a conservative yet equally efficacious approach compared to radical vulvectomy, which not only prevents local recurrence but also considerably reduces psychosexual morbidity.¹⁴²⁻¹⁵⁰

4.3.2. Management of Inguinal Lymph Nodes

Efficient inguinal lymph node management is pivotal in reducing mortality rates associated with early-stage vulvar cancers, considering that despite multimodal therapies, recurrences and metastases remain tied to high mortality risks.¹⁵⁰⁻¹⁵¹ Isolated inguinal lymph node dissection leads to elevated groin recurrence rates, necessitating the removal of both inguinal and femoral lymph nodes. Consequently, the present treatment paradigm mandates the separate excision of the primary tumor and lymph nodes.¹⁴⁷ All individuals with IB stage or resectable stage II vulvar cancer should undergo inguinofemoral lymphadenectomy.¹⁴⁸ The optimal number of resected lymph nodes for minimizing recurrence risk remains uncertain.¹⁴⁹ The three-incision technique stands as the standard for radical vulvectomy with bilateral inguinofemoral lymphadenectomy, offering commendable locoregional control and acceptable surgical morbidity¹⁵⁰.

4.3.3. Adjuvant Treatment


Adjuvant therapy denotes therapeutic interventions administered post-primary treatment of a neoplasm, aimed at diminishing the risk of locoregional or extrapelvic recurrence, typically when complete tumor removal through surgery was unattainable or lymph node metastasis is present. Radiotherapy, often in combination with chemotherapy, constitutes the cornerstone of adjuvant therapy for vulvar cancer.¹⁵¹ Indications encompass situations with (i) histologically confirmed lymph node metastasis or (ii) primary therapy for advanced-stage disease followed by radical tumor resection. Other considerations entail lymph vascular space invasion, deep invasion of the primary lesion, or substantial tumor size.¹⁵² In instances of positive sentinel lymph node (SLN) biopsy, complete bilateral inguinofemoral lymphadenectomy is recommended for macrometastases (>2 mm), while radiotherapy suffices for micrometastases (>0.2 mm–≤2 mm).¹⁵³ In cases where unilateral inguinofemoral lymphadenectomy is conducted and final pathology identifies positive lymph nodes (macrometastases >2mm), contralateral inguinofemoral lymphadenectomy is advised. For patients with two or more positive groin nodes or extracapsular spread following inguinofemoral lymphadenectomy, pelvic and groin radiotherapy is advocated.^{147,152-153} Excision margins < 8 mm necessitate re-excision or radiotherapy.¹⁴¹

5) Vaginal Cancer

Cervical, endometrial, or vulvar cancers are known to instigate primary or recurrent ailments within the vaginal region.¹⁵³⁻¹⁵⁴ The prognosis of vaginal cancer is intricately influenced by various factors such as the size and location of the initial tumor within the vaginal canal, histological subtype and grade, lymphovascular infiltration, regional lymph node involvement, and prior therapeutic interventions.¹⁵⁴⁻¹⁵⁶ Vaginal cancer is a relatively rare occurrence in the realm of gynecological malignancies, comprising merely 1-2 percent of all such cases in developed nations.¹⁵⁶⁻¹⁵⁸ The categorization of cases as vaginal carcinomas is typically considered after excluding origins from the cervix, urethra, or vulva, as per the guidelines provided by the International Federation of Gynecology and Obstetrics (FIGO).¹⁵⁹ A subset of vaginal cancer, known as primary duct carcinoma, accounts for approximately 3% of all malignancies arising from the female reproductive system. Squamous cell carcinoma, either in situ or invasive, affecting the vaginal canal, is seen in roughly 1 in 100,000 women. Due to its rarity, only two population-based case-control studies have been conducted to ascertain the etiology of this ailment.¹⁶⁰ In the United States, an estimated 3,000 cases are identified annually, leading to approximately 900 fatalities. Notably, ductal carcinomas are becoming more prevalent among young women, a trend attributed to the increasing incidence of precarious human papillomavirus (HPV) infections.¹⁶⁰⁻¹⁶¹(Fig.no.7)

5.1. Squamous Cell Carcinoma

Squamous Cell Carcinoma stands as the predominant histological type of vaginal cancer. Originating from the thin, flat epithelial cells that line the vaginal mucosa, these malignancies primarily manifest as squamous cell carcinomas.¹⁶²⁻¹⁶³ Squamous cell carcinoma comprises a substantial majority, accounting for around 80-90% of all primary vaginal malignancies.¹⁶⁴⁻¹⁶⁴ Within the domain of histological categorization, squamous cell carcinomas can be classified as differentiated [G1], moderately differentiated [G2], or poorly differentiated or undifferentiated [G3] based on histopathological characteristics.¹⁶⁵ Characterized by a relatively indolent growth pattern, these malignancies may evolve from a precursor state known as vaginal intraepithelial neoplasia (VAIN).¹⁶⁶ It is noteworthy that vaginal intraepithelial neoplasia [VAIN] can potentially serve as a precursor to squamous cell carcinoma of the vaginal mucosa, although the true malignant potential of VAIN remains uncertain.¹⁵⁹⁻¹⁶⁶ Instances of VAIN have been identified among women with prior history of gynecological cancer radiation.¹⁶⁵ This radiation-associated VAIN appears to exhibit a higher propensity for recurrence following surgical excision or ablation in comparison to non-radiation-related VAIN, potentially progressing to invasive malignancy.(Fig.no.7)¹⁶⁶⁻¹⁷⁰



Created in BioRender.com 

Fig.no. 7- Comprehensive Overview of vaginal cancer.

5.2. Adenocarcinoma

Adenocarcinoma stands as the predominant histological type of vaginal cancer, constituting approximately 15% of all cases.¹⁶⁷ Originating from the cells of the vaginal glands, these malignancies primarily manifest as adenocarcinomas. While these cancers are more frequently observed in women over the age of 50, they can also occur in individuals whose mothers were exposed to diethylstilbestrol (DES) during pregnancy.¹⁶⁷⁻¹⁶⁸ The typical age at diagnosis is 19 years, and a significant portion of patients, around 90%, are diagnosed with stage I–II disease. The risk of this

malignancy is not influenced by contraceptive use or pregnancy. Notably, vaginal endometrioid adenocarcinoma is most commonly associated with endometriosis.¹⁶⁹⁻¹⁷⁵

5.3. Treatment of Vaginal Cancer

Based on Stages Given the rarity of vaginal cancer, there exists significant debate and divergence concerning the optimal treatment approaches. Radiation and resection strategies can be applied for vaginal cancer when diagnosed at an early stage.¹⁷⁶ As outlined by FIGO guidelines, treatment strategies should be tailored based on disease stage and vaginal attachment location.

Stage I

Tumors confined to the vaginal mucosa, classified as FIGO stage I, are treated effectively with a combination of radiotherapy and surgery or radiotherapy alone. In stage I, lymph node involvement rates are generally low, ranging from 6 to 16%.¹⁷¹⁻¹⁷² Various surgical techniques have been documented, aiming to standardize the surgical approach. For patients with small neoplastic masses, mass excision is performed.¹⁶⁹⁻¹⁷¹ Additional procedures include entire simple vaginectomy,¹⁷² partial vaginectomy,¹⁷¹ and radical vaginectomy.¹⁷¹ Radical vaginectomy involves removal of affected vaginal tissue up to the pelvic sidewall.¹⁷³ In certain cases, vulva vaginectomy may be performed to achieve negative margins, involving removal of the lower portion of the vagina.¹⁷⁰⁻¹⁷¹ Several studies have reported survival rates ranging from 56-90% over a cumulative 5-year period in patients solely treated with surgery in FIGO stage I. Some researchers suggest adjuvant radiotherapy for patients at high risk of recurrence, yielding 5-year survival rates of 79-100%.¹⁷⁰⁻¹⁷³ The most commonly utilized radiotherapeutic technique involves a combination of intracavitary and interstitial therapy¹⁶⁹⁻¹⁷² with external beam radiation therapy (EBRT) in patients exhibiting increasing risk prognostic factors.¹⁷²⁻¹⁷³ For poorly differentiated or large tumors, EBRT is often recommended.¹⁷⁴ Among advanced-stage cancer patients, radiation therapy involving brachytherapy and beam radiation is crucial in the management of vaginal cancer.¹⁷⁵ Radiation therapy offers the advantage of vaginal preservation.¹⁷⁵ Employing CT simulation for 3D conformal treatment planning results in more effective tumor dosing.¹⁷⁸⁻¹⁸⁰

Stage II

Stage II vaginal cancer involves the neoplasia affecting the sub vaginal tissue area but not extending to the pelvic wall. Radiotherapy is the prevailing treatment modality for stage II disease. Standard radiation treatment typically employs a combination of brachytherapy and external beam radiation therapy (EBRT).¹⁷⁶ Radical surgery alone or in combination with radiotherapy is also commonly considered.¹⁷⁵ For stage II-IVA vaginal cancer, chemotherapy is frequently recommended as a radiosensitizer. Based on data from randomized trials, Perez et al. reported that 30% of patients were in stage II and 50% were in stage III. Multiple strategies can be employed to enhance radiation dosing to the primary tumor site. The chosen treatment strategy is influenced by the size and location of the tumor. Promising results in vaginal cancer treatment have been observed through the use of 5-FU and mitomycin in conjunction with radiotherapy and concurrent chemotherapy.¹⁷⁷ Further research is required to evaluate the therapeutic efficacy of various chemotherapeutic or chemoradiotherapeutic regimens.¹⁸¹⁻¹⁸⁵

Stage III/IV

For stage III vaginal cancer, a combination of EBRT with brachytherapy or EBRT alone is employed. Combined chemoradiation is found to yield superior metabolic and clinical responses in females with stage III and stage IV (advanced) vaginal cancer.¹⁷⁸ Similar to the treatment for stage III disease, stage IVA vaginal cancer is treated using a combination of EBRT and brachytherapy or EBRT alone.¹⁷⁸⁻¹⁷⁹ Palliative radiotherapy along with chemotherapy is typically recommended for the treatment of stage IVB vaginal cancer.¹⁷⁷⁻¹⁸⁹

5.4. Prevention of Vaginal Cancer

HPV Vaccination:

The human papillomavirus (HPV) has been linked to several mucosal cancers including vaginal, vulvar, anal, penile, and oropharyngeal cancers. HPV stands as the most prevalent sexually transmitted infection worldwide, with 50-80% of sexually active individuals acquiring it at some point in their lives.¹⁸⁰⁻¹⁸¹ Vaginal cancer accounts for 95% of all cervical cancer cases and the majority of HPV-related morbidity and mortality. The human papillomavirus vaccine Gardasil has been approved by the U.S. Food and Drug Administration (FDA) for the prevention of precancer and cancer in the vagina. Gardasil effectively prevents infections caused by the most common strains of HPV,¹⁸²⁻¹⁸³ which primarily target the skin, anogenital, and oral mucosal epithelial cells.¹⁸⁴⁻¹⁹⁰

Regular Gynecologic Examinations

Women with risk factors for vaginal cancer should undergo periodic early-stage gynecologic examinations to mitigate the risk of precancerous and cancerous developments within the vaginal region.¹⁸⁹⁻¹⁹² These examinations encompass evaluations of the vagina, uterus, cervix, and other reproductive organs to detect any unexpected abnormalities.¹⁸⁶ Diagnostic techniques such as the Pap test for detecting vaginal cancer through epithelial lesion assessment, Cervicography which captures vaginal imagery for size assessment, and other methods are employed for detecting vaginal cancer¹⁸⁵⁻¹⁸⁸. Different factors contribute to the development of various types of cancer. Ongoing research aims to uncover the etiology of vaginal cancer development and establish preventative measures.¹⁹³⁻²⁰⁵

Importance of Artificial intelligence in Female Reproductive Organ Cancer

The imperative necessity for accurate and timely diagnostic and prognostic predictions in enhancing patient survival rates has prompted the evolution of statistical and computational methodologies. This, in turn, has invigorated the scientific and research communities to explore innovative approaches such as artificial intelligence (AI), particularly machine learning (ML) and deep learning (DL), within the realm of clinical research for diverse types of cancers. These advancements have notably heightened prediction capabilities, particularly in the context of cancers affecting women. Over the past decade, AI has made substantial contributions in addressing a spectrum of biomedical challenges, including cancer. With the capacity for autonomous learning and robust logical reasoning, AI technologies like ML have the potential to revolutionize existing paradigms in anti-cancer drug development. This chapter delves into the pivotal role of AI, ML, and DL in the domains of diagnosis, prognosis, and treatment pertaining to cancers specific to women.²⁰⁶

Artificial intelligence (AI), notably encompassing machine learning (ML) and deep learning (DL), has gained extensive traction within contemporary clinical cancer research, yielding an unparalleled enhancement in predictive accuracy. AI-driven models harnessed by advanced algorithms have proven instrumental in prognosticating and diagnosing cancer. These methodologies prominently contribute to augmenting the precision of forecasts pertaining to cancer susceptibility, recurrence, and survival rates.²⁰⁷⁻²⁰⁸

Overview of Artificial Intelligence (AI): AI encompasses the integration of machine learning (ML), with deep learning (DL) nested within the ML paradigm. Machine learning encompasses diverse methodologies including supervised learning, unsupervised learning, and reinforcement learning. Supervised learning encompasses techniques such as classification and regression. Unsupervised learning entails dimensionality reduction and clustering techniques, while reinforcement learning involves both positive and negative reinforcement learning paradigms. (Fig. no. 8)²⁰⁹




Fig. no. 8- Overview of Artificial Intelligence (AI)

Platinum-based chemotherapy stands as the established therapeutic modality for individuals with advanced-stage ovarian cancer. Electromagnetic (EM) tracking technology represents an emerging innovation that has been implemented for applicator reconstruction within the domain of Brachytherapy in recent times. Utilization of Neural Networks in Therapeutics: Employing a comprehensive deep deconvolutional neural network (DDNN) presents a comprehensive framework enabling efficient training and rapid testing. This architecture comprises two pivotal components: an encoder network and a decoder network. The encoder network is responsible for capturing the visual features of a medical image, while the decoder network employs deconvolution techniques to restore the initial resolution²⁰⁹⁻²¹⁰.

The automatic segmentation method commonly used in clinical practice is based on the atlas technique,¹⁹⁰⁻¹⁹⁴ however, the segmentation results largely depend on the registration algorithm applied and the uncertainty of single-atlas segmentation.¹⁹⁵⁻¹⁹⁶ Compared with the single-atlas-based automatic segmentation, the robustness of multi-atlas automatic segmentation is improved; however, this approach is prone to topological errors and requires additional calculation time.¹⁹⁶ Recently, convolutional neural networks (CNNs) have been successfully applied to the automatic segmentation of medical images.¹⁹⁷⁻¹⁹⁹ As a deep learning algorithm, it has achieved excellent segmentation performance under various architectures of CNNs. Moreover, the automatic segmentation method based on a CNN has been introduced into radiotherapy plans. Recently, AI applications have been explored in cervical cancer for target volume and normal tissue segmentation on computed tomography (CT) images.¹⁹⁸ Low efficiency and inconsistent standards in the manual contouring process were solved by automatic segmentation. Although the available results are noted to be encouraging, a larger volume of training datasets is needed to improve generalizability.¹⁹⁹⁻²¹⁰

Applications of Artificial Intelligence and machine learning²¹¹⁻²¹²

- Precision Medicine

Precision medicine represents a sophisticated utilization of machine learning (ML) to propose potential prognosis and treatment avenues, accounting for patients' medical histories and ongoing therapeutic interventions. Comprehending this implementation through ML necessitates a thorough exploration of its underpinning concepts. This entails categorizing ML within the domains of supervised learning, unsupervised learning, and reinforcement learning [26].

- Computer-Aided Diagnosis (CAD)

Computational biology amalgamates biological concepts with information technology methodologies, thus enhancing our comprehension of diverse biological phenomena and optimizing diagnostic and research procedures. Omics technologies play a pivotal role in generating and comprehending biological data. Data from tests assessing various parameters in the human body, alongside outcomes from comprehensive blood counts and biopsies, contribute to the datasets used by these models. A plethora of technologies and programming languages are harnessed in AI model formulation. This section highlights contemporary technologies popularized by various applications, including the Apple Watch.

Originating as "expert systems in medicine" during the 1950s, an early attempt at fusing computers with biology, computer-aided diagnosis (CAD) embodies the implementation of these ideas alongside systems that emulate the diagnostic reasoning methods of healthcare experts. Presently, CAD plays a role in various processes such as medical image analysis, radiology, and oncology diagnosis.

- Challenges confront healthcare organizations seeking to implement time-efficient AI. Rule-based methods are prevalent in medical record systems, while ML models have garnered prominence in the healthcare domain. Although they excel in certain scenarios due to limited computational resources and data availability (e.g., medical readmissions), it is unsurprising that they are increasingly embraced by clinicians, as they facilitate efficient data analysis and predictions.

- Application of deep learning techniques to cancer imaging can aid pathologists in early-stage cancer detection and classification, enabling timely and effective treatments to enhance patient survival. The potential value of AI in formulating an adaptive cancer therapy framework is noteworthy. The realization of effective and secure AI-enabled adaptive cancer therapy necessitates clinical trials to solidify the parameters and modalities of such an approach.

Conclusion

Incidence of malignancies affecting the female reproductive system tends to be more prevalent among postmenopausal women. Nevertheless, a noteworthy rise in the diagnosis of primary vaginal cancer in younger women has been documented, particularly in regions with a high prevalence of human immunodeficiency virus (HIV) infection. This trend is closely linked to the persistence of high-risk human papillomavirus (HPV) infection. It is imperative to underscore the importance of primary prevention through the implementation of prophylactic HPV vaccination. Upon suspicion of primary vaginal cancer, a confirmatory histological assessment via biopsy becomes essential. Clinical staging procedures akin to those used for cervical cancer have been employed, although imaging techniques are also found beneficial in aiding the intricate task of accurate staging. The therapeutic approach to combat vaginal cancer often involves intensive radiotherapy or chemotherapy regimens, which may potentially result in lasting impairment of reproductive function. Consequently, safeguarding fertility becomes a pivotal aspect of cancer management, especially among the younger demographic. To overcome harmful effects of therapies world turns towards the techniques like artificial intelligence, machine learning, etc. in these types of techniques diagnosis of diseases very precision and accurate, so that delay in treatment can be avoided.

AI and ML can be recognized as antecedents to an emerging and enhanced medical paradigm that not only demands diminished human exertion but also mitigates the potential for human fallibility. The eventual requirement for clinical trials assessing the application of adaptive therapeutic strategies within cancer care becomes imperative to concretely define the parameters and methodologies underpinning a proficient and secure AI-enabled adaptive cancer therapy.

REFERENCES

1. Pang, T., Wong, J.H.D., Ng, W.L. and Chan, C.S., 2020. Deep learning radiomics in breast cancer with different modalities: Overview and future. *Expert Systems with Applications*, 158, p.113501.
2. Cancer-Its various types along with causes, symptoms, treatments and stages, in: cancer info guide, 2009. <http://www.cancer-info-guide.com/> (August 2023).
3. Mieszkowski, M. R., Cancer – A biophysicist’s point of view. In: *Digital Recordings*. 04 Sept. 2006. <http://www.digitalrecordings.com/publ/cancer.html> (August 2023).
4. Immune system. In: *Kids Health*. 2010. http://kidshealth.org/parent/general/body_basics/immune.html# (August 2023).
5. Helmberg, A, Carcinogenesis. 2010. <http://helmberg.at/carcinogenesis.htm> (August 2023).
6. Diet and Physical Activity: What’s the Cancer Connection? In: *Prevention & Early Detection*. 22 Oct. 2009. http://www.cancer.org/docroot/PE_D/content/PED_3_1x_Link_Between_Lifestyle_and_CancerMarch03.asp (17 Mar. 2010).
7. Margot. New SEER Report Documents High Risk of Second Cancers in Cancer Survivors. *Oncology Times*. 2007; 29(5): 8.
8. Ershler W.B. The Influence of Advanced Age on Cancer Occurrence and Growth. In: Balducci L., Extermann M, editors. *Biological Basis of Geriatric Oncology*. Springer US; 2005; 124: 75-87.
9. Nofech-Mozes, S.; Trudeau, M.; Kahn, H.K.; Dent, R.; Rawlinson, E.; Sun, P.; Narod, S.A.; Hanna, W.M. Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers. *Breast Cancer Res. Treat.* 2009, 118, 131–137.
10. Schnitt, S.J.; Moran, M.S.; Giuliano, A.E. Lumpectomy Margins for Invasive Breast Cancer and Ductal Carcinoma in Situ: Current Guideline Recommendations, Their Implications, and Impact. *JCO* 2020, 38, 2240–2245.
11. Fisher, B.; Anderson, S.; Bryant, J.; Margolese, R.G.; Deutsch, M.; Fisher, E.R.; Jeong, J.-H.; Wolmark, N. Twenty-Year Follow-up of a Randomized Trial Comparing Total Mastectomy, Lumpectomy, and Lumpectomy plus Irradiation for the Treatment of Invasive Breast Cancer. *N. Engl. J. Med.* 2002, 347, 1233–1241.
12. Fisher, B.; Montague, E.; Redmond, C.; Deutsch, M.; Brown, G.R.; Zauber, A.; Hanson, W.F.; Wong, A. Findings from NSABP Protocol No. B-04-comparison of radical mastectomy with alternative treatments for primary breast cancer. I. Radiation compliance and its relation to treatment outcome. *Cancer* 1980, 46, 1–13.
13. Sener, S.F. Advances in axillary surgery for breast cancer 2019. *J. Surg. Oncol.* 2019.
14. Grubbé, E.H. Priority in the Therapeutic Use of X-rays. *Radiology* 1933, 21, 156–162.
15. Boyages, J. Radiation therapy and early breast cancer: Current controversies. *Med. J. Aust.* 2017, 207, 216–222.
16. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG); Darby, S.; McGale, P.; Correa, C.; Taylor, C.; Arriagada, R.; Clarke, M.; Cutter, D.; Davies, C.; Ewertz, M.; et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: Meta-analysis of individual patient data for 10,801 women in 17 randomised trials. *Lancet* 2011, 378, 1707–1716.
17. EBCTCG (Early Breast Cancer Trialists’ Collaborative Group). Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: Meta-analysis of individual patient data for 8135 women in 22 randomised trials. *Lancet* 2014, 383, 2127–2135.
18. Bartelink, H.; Maingon, P.; Poortmans, P.; Weltens, C.; Fourquet, A.; Jager, J.; Schinagl, D.; Oei, B.; Rodenhuis, C.; Horiot, J.-C.; et al. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. *Lancet Oncol.* 2015, 16, 47–56.

19. Whelan, T.J.; Olivotto, I.A.; Parulekar, W.R.; Ackerman, I.; Chua, B.H.; Nabid, A.; Vallis, K.A.; White, J.R.; Rousseau, P.; Fortin, A.; et al. Regional Nodal Irradiation in Early-Stage Breast Cancer. *N. Engl. J. Med.* 2015, 373, 307–316.
20. Cheng, Y.; Nie, X.; Ji, C.; Lin, X.; Liu, L.; Chen, X.; Yao, H.; Wu, S. Long-Term Cardiovascular Risk After Radiotherapy in Women With Breast Cancer. *JAMA* 2017, 6.
21. Taylor, C.W.; Kirby, A.M. Cardiac Side-effects From Breast Cancer Radiotherapy. *Clin. Oncol.* 2015, 27, 621–629.
22. Delaney, G.; Jacob, S.; Featherstone, C.; Barton, M. The role of radiotherapy in cancer treatment: Estimating optimal utilization from a review of evidence-based clinical guidelines. *Cancer* 2005, 104, 1129–1137.
23. Gilreath, C.; Boerma, M.; Qin, Z.; Hudson, M.K.; Wang, S. The Hypoxic Microenvironment of Breast Cancer Cells Promotes Resistance in Radiation Therapy. *Front. Oncol.* 2020, 10, 629422.
24. Krishnamachary, B.; Penet, M.-F.; Nimmagadda, S.; Mironchik, Y.; Raman, V.; Solaiyappan, M.; Semenza, G.L.; Pomper, M.G.; Bhujwalla, Z.M. Hypoxia Regulates CD44 and Its Variant Isoforms through HIF-1 α in Triple Negative Breast Cancer. *PLoS ONE* 2012, 7, e44078.
25. Kim, J.; Tchernyshyov, I.; Semenza, G.L.; Dang, C.V. HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia. *Cell Metab.* 2006, 3, 177–185.
26. Jiang, B.H.; Agani, F.; Passaniti, A.; Semenza, G.L. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: Involvement of HIF-1 in tumor progression. *Cancer Res.* 1997, 57, 5328–5335.
27. Blanche, C.; Moore, J.W.; Talks, K.L.; Houlbrook, S.; Harris, A.L. Relationship of hypoxia-inducible factor (HIF)-1 α and HIF-2 α expression to vascular endothelial growth factor induction and hypoxia survival in human breast cancer cell lines. *Cancer Res.* 2000, 60, 7106–7113.
28. Qi, X.S.; Pajonk, F.; McCloskey, S.; Low, D.A.; Kupelian, P.; Steinberg, M.; Sheng, K. Radioresistance of the breast tumor is highly correlated to its level of cancer stem cell and its clinical implication for breast irradiation. *Radiother. Oncol.* 2017, 124, 455–461.
29. Lagadec, C.; Vlashi, E.; Della Donna, L.; Meng, Y.; Dekmezian, C.; Kim, K.; Pajonk, F. Survival and self-renewing capacity of breast cancer initiating cells during fractionated radiation treatment. *Breast Cancer Res.* 2010, 12, R13.
30. Lock, F.E.; McDonald, P.C.; Lou, Y.; Serrano, I.; Chafe, S.C.; Ostlund, C.; Aparicio, S.; Winum, J.-Y.; Supuran, C.T.; Dedhar, S. Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche. *Oncogene* 2013, 32, 5210–5219.
31. He, M.Y.; Rancoule, C.; Rehailla-Blanchard, A.; Espenel, S.; Trone, J.-C.; Bernichon, E.; Guillaume, E.; Vallard, A.; Magné, N. Radiotherapy in triple-negative breast cancer: Current situation and upcoming strategies. *Crit. Rev. Oncol. Hematol.* 2018, 131, 96–101.
32. Nabholz, J.-M.; Gligorov, J. The role of taxanes in the treatment of breast cancer. *Expert Opin. Pharmacother.* 2005, 6, 1073–1094.
33. Penel, N.; Adenis, A.; Bocci, G. Cyclophosphamide-based metronomic chemotherapy: After 10 years of experience, where do we stand and where are we going? *Crit. Rev. Oncol. Hematol.* 2012, 82, 40–50.
34. Gewirtz, D. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. *Biochem. Pharmacol.* 1999, 57, 727–741.
35. Moos, P.J.; Fitzpatrick, F.A. Taxanes propagate apoptosis via two cell populations with distinctive cytological and molecular traits. *Cell Growth Differ.* 1998, 9, 687–697.

36. Chira, C.; Kirova, Y.M.; Liem, X.; Campana, F.; Peurien, D.; Amessis, M.; Fournier-Bidoz, N.; Pierga, J.-Y.; Dendale, R.; Bey, P.; et al. Helical Tomotherapy for Inoperable Breast Cancer: A New Promising Tool. *BioMed Res. Int.* 2013, 2013, 264306.
37. Montemurro, F.; Nuzzolese, I.; Ponzzone, R. Neoadjuvant or adjuvant chemotherapy in early breast cancer? *Expert Opin. Pharmacother.* 2020, 21, 1071–1082.
38. Broët, P.; Scholl, S.M.; de la Rochefordière, A.; Fourquet, A.; Moreau, T.; De Rycke, Y.; Asselain, B.; Pouillart, P. Short and long-term effects on survival in breast cancer patients treated by primary chemotherapy: An updated analysis of a randomized trial. *Breast Cancer Res. Treat.* 1999, 58, 151–156.
39. van der Hage, J.A.; van de Velde, C.J.; Julien, J.P.; Tubiana-Hulin, M.; Vandervelden, C.; Duchateau, L. Preoperative chemotherapy in primary operable breast cancer: Results from the European Organization for Research and Treatment of Cancer trial 10902. *J. Clin. Oncol.* 2001, 19, 4224–4237.
40. Fisher, B.; Bryant, J.; Wolmark, N.; Mamounas, E.; Brown, A.; Fisher, E.R.; Wickerham, D.L.; Begovic, M.; DeCillis, A.; Robidoux, A.; et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. *J. Clin. Oncol.* 1998, 16, 2672–2685.
41. von Minckwitz, G.; Rezai, M.; Tesch, H.; Huober, J.; Gerber, B.; Zahm, D.M.; Hilfrich, J.; Costa, S.D.; Dubsy, P.; Blohmer, J.U.; et al. Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer—The Phase III NeoAdjuvant Trial Add-on (NaTaN) study (GBG 36/ABCSG 29). *Eur. J. Cancer* 2016, 64, 12–21.
42. Gonzalez-Angulo, A.M.; Lei, X.; Alvarez, R.H.; Green, M.C.; Murray, J.L.; Valero, V.; Koenig, K.B.; Ibrahim, N.K.; Litton, J.K.; Nair, L.; et al. Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer. *Clin. Breast Cancer* 2015, 15, 325–331.
43. Early Breast Cancer Trialists' Collaborative Group (EBCTCG); Peto, R.; Davies, C.; Godwin, J.; Gray, R.; Pan, H.C.; Clarke, M.; Cutter, D.; Darby, S.; McGale, P.; et al. Comparisons between different polychemotherapy regimens for early breast cancer: Meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. *Lancet* 2012, 379, 432–444.
44. Citron, M.L.; Berry, D.A.; Cirincione, C.; Hudis, C.; Winer, E.P.; Gradishar, W.J.; Davidson, N.E.; Martino, S.; Livingston, R.; Ingle, J.N.; et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. *J. Clin. Oncol.* 2003, 21, 1431–1439.
45. Sparano, J.A.; Wang, M.; Martino, S.; Jones, V.; Perez, E.A.; Saphner, T.; Wolff, A.C.; Sledge, G.W.; Wood, W.C.; Davidson, N.E. Weekly paclitaxel in the adjuvant treatment of breast cancer. *N. Engl. J. Med.* 2008, 358, 1663–1671.
46. Berry, D.A.; Cirincione, C.; Henderson, I.C.; Citron, M.L.; Budman, D.R.; Goldstein, L.J.; Martino, S.; Perez, E.A.; Muss, H.B.; Norton, L.; et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. *JAMA* 2006, 295, 1658–1667.
47. Paik, S.; Tang, G.; Shak, S.; Kim, C.; Baker, J.; Kim, W.; Cronin, M.; Baehner, F.L.; Watson, D.; Bryant, J.; et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. *J. Clin. Oncol.* 2006, 24, 3726–3734.
48. Sparano, J.A.; Gray, R.J.; Makower, D.F.; Pritchard, K.I.; Albain, K.S.; Hayes, D.F.; Geyer, C.E.; Dees, E.C.; Perez, E.A.; Olson, J.A.; et al. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. *N. Engl. J. Med.* 2015, 373, 2005–2014.

49. Anampa, J.; Makower, D.; Sparano, J.A. Progress in adjuvant chemotherapy for breast cancer: An overview. *BMC Med.* 2015, 13, 195.
50. Cardoso, F.; Senkus, E.; Costa, A.; Papadopoulos, E.; Aapro, M.; André, F.; Harbeck, N.; Aguilar Lopez, B.; Barrios, C.H.; Bergh, J.; et al. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). *Ann. Oncol.* 2018, 29, 1634–1657.
51. Tao, J.J.; Visvanathan, K.; Wolff, A.C. Long term side effects of adjuvant chemotherapy in patients with early breast cancer. *Breast* 2015, 24 (Suppl 2), S149–S153.
52. Coley, H.M. Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. *Cancer Treat. Rev.* 2008, 34, 378–390.
53. Fojo, T.; Menefee, M. Mechanisms of multidrug resistance: The potential role of microtubule-stabilizing agents. *Ann. Oncol.* 2007, 18, v3–v8.
54. Faneyte, I.F.; Kristel, P.M.P.; Maliepaard, M.; Scheffer, G.L.; Scheper, R.J.; Schellens, J.H.M.; van de Vijver, M.J. Expression of the breast cancer resistance protein in breast cancer. *Clin. Cancer Res.* 2002, 8, 1068–1074.
55. Kamath, K.; Wilson, L.; Cabral, F.; Jordan, M.A. BetaIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. *J. Biol. Chem.* 2005, 280, 12902–12907.
56. Rouzier, R.; Rajan, R.; Wagner, P.; Hess, K.R.; Gold, D.L.; Stec, J.; Ayers, M.; Ross, J.S.; Zhang, P.; Buchholz, T.A.; et al. Microtubule-associated protein tau: A marker of paclitaxel sensitivity in breast cancer. *Proc. Natl. Acad. Sci. USA* 2005, 102, 8315–8320.
57. Sládek, N.E. Aldehyde dehydrogenase-mediated cellular relative insensitivity to the oxazaphosphorines. *Curr. Pharm. Des.* 1999, 5, 607–625.
58. Gonzalez-Angulo, A.M.; Lei, X.; Alvarez, R.H.; Green, M.C.; Murray, J.L.; Valero, V.; Koenig, K.B.; Ibrahim, N.K.; Litton, J.K.; Nair, L.; et al. Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer. *Clin. Breast Cancer* 2015, 15, 325–331.
59. Early Breast Cancer Trialists' Collaborative Group (EBCTCG); Peto, R.; Davies, C.; Godwin, J.; Gray, R.; Pan, H.C.; Clarke, M.; Cutter, D.; Darby, S.; McGale, P.; et al. Comparisons between different polychemotherapy regimens for early breast cancer: Meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. *Lancet* 2012, 379, 432–444.
60. Citron, M.L.; Berry, D.A.; Cirincione, C.; Hudis, C.; Winer, E.P.; Gradishar, W.J.; Davidson, N.E.; Martino, S.; Livingston, R.; Ingle, J.N.; et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. *J. Clin. Oncol.* 2003, 21, 1431–1439.
61. Sparano, J.A.; Wang, M.; Martino, S.; Jones, V.; Perez, E.A.; Saphner, T.; Wolff, A.C.; Sledge, G.W.; Wood, W.C.; Davidson, N.E. Weekly paclitaxel in the adjuvant treatment of breast cancer. *N. Engl. J. Med.* 2008, 358, 1663–1671.
62. Berry, D.A.; Cirincione, C.; Henderson, I.C.; Citron, M.L.; Budman, D.R.; Goldstein, L.J.; Martino, S.; Perez, E.A.; Muss, H.B.; Norton, L.; et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. *JAMA* 2006, 295, 1658–1667.
63. Paik, S.; Tang, G.; Shak, S.; Kim, C.; Baker, J.; Kim, W.; Cronin, M.; Baehner, F.L.; Watson, D.; Bryant, J.; et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. *J. Clin. Oncol.* 2006, 24, 3726–3734.
64. Sparano, J.A.; Gray, R.J.; Makower, D.F.; Pritchard, K.I.; Albain, K.S.; Hayes, D.F.; Geyer, C.E.;

- Dees, E.C.; Perez, E.A.; Olson, J.A.; et al. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. *N. Engl. J. Med.* 2015, 373, 2005–2014.
65. Anampa, J.; Makower, D.; Sparano, J.A. Progress in adjuvant chemotherapy for breast cancer: An overview. *BMC Med.* 2015, 13, 195.
66. Cardoso, F.; Senkus, E.; Costa, A.; Papadopoulos, E.; Aapro, M.; André, F.; Harbeck, N.; Aguilar Lopez, B.; Barrios, C.H.; Bergh, J.; et al. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). *Ann. Oncol.* 2018, 29, 1634–1657.
67. Tao, J.J.; Visvanathan, K.; Wolff, A.C. Long term side effects of adjuvant chemotherapy in patients with early breast cancer. *Breast* 2015, 24 (Suppl 2), S149–S153.
68. Coley, H.M. Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. *Cancer Treat. Rev.* 2008, 34, 378–390.
69. Fojo, T.; Menefee, M. Mechanisms of multidrug resistance: The potential role of microtubule-stabilizing agents. *Ann. Oncol.* 2007, 18, v3–v8.
70. Faneyte, I.F.; Kristel, P.M.P.; Maliepaard, M.; Scheffer, G.L.; Scheper, R.J.; Schellens, J.H.M.; van de Vijver, M.J. Expression of the breast cancer resistance protein in breast cancer. *Clin. Cancer Res.* 2002, 8, 1068–1074.
71. Kamath, K.; Wilson, L.; Cabral, F.; Jordan, M.A. BetaIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. *J. Biol. Chem.* 2005, 280, 12902–12907.
72. Rouzier, R.; Rajan, R.; Wagner, P.; Hess, K.R.; Gold, D.L.; Stec, J.; Ayers, M.; Ross, J.S.; Zhang, P.; Buchholz, T.A.; et al. Microtubule-associated protein tau: A marker of paclitaxel sensitivity in breast cancer. *Proc. Natl. Acad. Sci. USA* 2005, 102, 8315–8320.
73. Sládek, N.E. Aldehyde dehydrogenase-mediated cellular relative insensitivity to the oxazaphosphorines. *Curr. Pharm. Des.* 1999, 5, 607–625.
74. Simonyan K, Zisserman A. Very deep convolutional networks for large-scale image recognition. *Computer Science.* 2014. Available from: URL, <https://arxiv.org/pdf/1409.1556.pdf>.
75. Girshick R, Donahue J, Darrell T, Malik J. Rich feature hierarchies for accurate object detection and semantic segmentation. Available from: URL, <https://arxiv.org/abs/1311.2524>.
76. Kyono T, Gilbert FJ, van der Schaar M. Improving workflow efficiency for mammography using machine learning. *J Am Coll Radiol* 2019 May 30. pii: S1546-1440(19)30596-4.
77. Brouwers P, van Werkhoven E, Bartelink H, et al. Predictors for poor cosmetic outcome in patients with early stage breast cancer treated with breast conserving therapy: results of the Young boost trial. *Radiother Oncol* 2018;128:434e41.
78. Esmaeilzadeh AA, et al., Correction: Recent advances on the electrochemical and optical biosensing strategies for monitoring microRNA21: a review, *Analytical Methods*, 2023
79. Esmaeilzadeh AA, et al., Cytotoxic study of green synthesized pure and Ag-doped α -Fe₂O₃ nanoparticles on breast cancer (MCF-7) cell line, *Nanomedicine Research Journal*, 2022 7 (4), 370-377
80. Esmaeilzadeh AA, et al., Recent advances on electrochemical and optical biosensing strategies for monitoring of microRNA-21: A review, *Analytical Methods*, 2022 15 (1), 132- 132
81. Esmaeilzadeh AA, et al., Study of Silybin in Plant Effective Substance for use in targeted liposomal nanoparticles in the treatment of liver cancer, *Archives of Pharmacy Practice*, 2020 11 (1), 35
82. F Beiranvandi, et al., Investigation Of Medical Services In Patients With Diabetes And Cardio Vascular Disease & High Blood Pressure In ICU With Radiological & Pathology Point: The Original Article, *Journal of Pharmaceutical Negative Results*, 2022 4417-4425
83. M Milanifard, Effects of Micronutrients in Improving Fatigue, Weakness and Irritability, *GMJ Medicine*, 2021 5 (1), 391-395

84. E Yahaghi, F Khamesipour, F Mashayekhi, F Safarpour Dehkordi, MH Sakhaei, M Masoudimanesh, MK Khameneie. Helicobacter pylori in vegetables and salads: genotyping and antimicrobial resistance properties. *BioMed Research International*. 2014 12;2014: 757941.
85. M Yazdani, A Rahmani, E Tahmasebi, H Tebyanian, A Yazdani, SA Mosaddad. Current and Advanced Nanomaterials in Dentistry as Regeneration Agents: An Update. *Mini Reviews in Medicinal Chemistry*. 2021;21(7):899-918.
86. S Sayad, SAY Ahmadi, M Moradi, R Nekouian, K Anbari, F Shahsavari, A metaanalysis on diagnostic accuracy of serum HLA-G level in breast cancer, *Expert Review of Precision Medicine and Drug Development*, 2020 5 (2), 109-114
87. Esmaeilzadeh, A.A. and Nasirzadeh, F., 2023. Uterus Cancer. *Eurasian Journal of Chemical, Medicinal and Petroleum Research*, 2(5), pp.63-83.
88. A Fattahi, A Jahanbakhshi, et al., Penetrating sacral injury with a wooden foreign body, *Case reports in medicine* 2018.
89. MH Abdollahi, et al. The effect of preoperative intravenous paracetamol administration on postoperative fever in pediatric cardiac surgery. *Nigerian medical journal: journal of the Nigeria Medical Association*. 2014; 55(5): 379.
90. A Afshari, et al., Biomaterials and Biological Parameters for Fixed-Prosthetic Implant-Supported Restorations: A Review Study. *Advances in Materials Science and Engineering*. 2022;2022:2638166.
91. A Afshari, et al. Free-Hand versus Surgical Guide Implant Placement. *Advances in Materials Science and Engineering*. 2022;2022:6491134.
92. SS Aghili, et al., COVID-19 Risk Management in Dental Offices: A Review Article. *Open Access Maced J Med Sci*. 2022 Nov 04; 10(F):763-772.
93. SE Ahmadi, et al., Succinct review on biological and clinical aspects of Coronavirus disease 2019 (COVID-19), *Romanian Journal of Military Medicine*, 2022,356-365.
94. H Ansari lari, et al. In Vitro Comparison of the Effect of Three Types of Heat-Curing Acrylic Resins on the Amount of Formaldehyde and Monomer Release as well as Biocompatibility. *Advances in Materials Science and Engineering*. 2022;2022:8621666.
95. DH Birman, Investigation of the Effects of Covid-19 on Different Organs of the Body, *Eurasian Journal of Chemical, Medicinal and Petroleum Research*, 2023, 2 (1), 24-36.
96. S Birmangi, A Review of the Effect of Corona on the Human Brain – Short Review, *Eurasian Journal of Chemical, Medicinal and Petroleum Research*, 2022, 1 (3), 80-87.
97. H Danesh, et al., Pharmacological Evaluation of Covid 19 Vaccine in Acute and Chronic Inflammatory Neuropathies, *Journal of Medicinal and Chemical Sciences*, 2022, 561- 570.
98. MN Darestani, et al., Assessing the Surface Modifications of Contaminated Sandblasted and Acid-Etched Implants Through Diode Lasers of Different Wavelengths: An In-Vitro Study. *Photobiomodulation, Photomedicine, and Laser Surgery*. 2023.
99. R Dargahi, et al., Does coronavirus disease affect sleep disorders in the third trimester of pregnancy in women with low back pain? *International Journal of Women's Health and Reproduction Sciences*. 2021; 9(4):268-273.
100. M Eidi, et al., A comparison of preoperative ondansetron and dexamethasone in the prevention of post-tympanoplasty nausea and vomiting. *Iranian Journal of Medical Sciences*. 2012; 37(3):166-172.
101. Eidy M, Ansari M, Hosseinzadeh H, Kolahdouzan K. Incidence of back pain following spinal anesthesia and its relationship to various factors in 176 patients. *Pakistan Journal of Medical Sciences*. 2010; 26(4):778-781.
102. E Tahmasebi, M Alam, M Yazdani, H Tebyanian, A Yazdani, A Seifalian, et al. Current biocompatible materials in oral regeneration: a comprehensive overview of composite materials. *Journal of Materials Research and Technology*. 2020;9(5):11731-55.

103. E Yahaghi, F Khamesipour, F Mashayekhi, F Safarpour Dehkordi, MH Sakhaei, M Masoudimanesh, MK Khameneie. *Helicobacter pylori* in vegetables and salads: genotyping and antimicrobial resistance properties. *BioMedResearch International*. 2014 12;2014: 757941.
104. M Yazdani, A Rahmani, E Tahmasebi, H Tebyanian, A Yazdani, SA Mosaddad. Current and Advanced Nanomaterials in Dentistry as Regeneration Agents: An Update. *Mini Reviews in Medicinal Chemistry*. 2021;21(7):899-918.
105. S Sayad, SAY Ahmadi, M Moradi, R Nekouian, K Anbari, F Shahsavari, A metaanalysis on diagnostic accuracy of serum HLA-G level in breast cancer, *Expert Review of Precision Medicine and Drug Development*, 2020 5 (2), 109-114.
106. AR Baghestani, P Shahmirzalou, S Sayad, ME Akbari, F Zayeri, Comparison cure rate models by DIC criteria in Breast Cancer data, *Asian Pacific journal of cancer prevention: APJCP*, 2018 19 (6), 1601
107. S Sayad, SA Dastgheib, et al., Association of PON1, LEP and LEPR Polymorphisms with Susceptibility to Breast Cancer: A Meta-Analysis, *Asian Pacific Journal of Cancer Prevention: APJCP*, 2021 22 (8), 2323.
108. SAY Ahmadi, S Sayad, et al., Expression of angiogenesis-related genes in a group of Iranian cases of breast cancer, *Current Pharmacogenomics and Personalized Medicine*, 2020 17(3) 197-205.
109. S Sayad, SAY Ahmadi, R Nekouian, M Panahi, K Anbari, Epidemiological and pathological characteristics of postsurgical cases of invasive breast cancer among ethnicities of Iran in 2018: A single center cross-sectional study, *Current Pharmacogenomics and Personalized Medicine*, 2020.
110. A.A Esmailzadeh; F Nasirzadeh, Investigation of Chemicals on Breast Cancer, *Eurasian Journal of Chemical, Medicinal and Petroleum Research*, 2022, 1(5), 51-75.
111. A.A. Esmailzadeh; Sh Kordjazi; A Salari, A Short Review on the Use of Chemotherapy Drugs in Uterine Cancer, *Eurasian Journal of Chemical, Medicinal and Petroleum Research*, 2022, 1(5), 87-98.
112. Basta A, Bidziński M, Bieńkiewicz A, Blecharz P, Bodnar L, Jach R, Knapp P, Kojs Z, Kotarski J, Markowska J, Misiek M, Sznurkowski J, Wicherek Ł, Sawicki W, Timorek A, Bahyrycz J, Mądry R (2015) Recommendation of the Polish society of oncological gynaecology on the diagnosis and treatment of epithelial ovarian cancer. *Oncol Clin Pract* 11(5):11
113. Prat J, *Oncology FCoG* (2014) Staging classification for cancer of the ovary, fallopian tube, and peritoneum. *Int J Gynaecol Obstet* 124(1):1–5.
114. ESGO.Guidelines ESoGO (2015) Advanced (stage III-IV) ovarian cancer surgery. Quality indicators. Complete report. ESGO, Prague.
115. EMA (2009) EMA approval: avastin authorization details. EMA, UK
116. Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, Tsuda H, Sugiyama T, Kodama S, Kimura E, Ochiai K, Noda K, Grp JGO (2009) Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. *Lancet* 374(9698):1331–1338.
117. Katsumata N, Yasuda M, Isonishi S, Takahashi F, Michimae H, Kimura E, Aoki D, Jobo T, Kodama S, Terauchi F, Sugiyama T, Ochiai K, Grp JGO (2013) Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. *Lancet Oncol* 14(10):1020–1026.
118. Chan JK, Brady MF, Penson RT, Huang H, Birrer MJ, Walker JL, DiSilvestro PA, Rubin SC, Martin LP, Davidson SA, Huh WK, O'Malley DM, Boente MP, Michael H, Monk BJ (2016) Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. *N Engl J Med* 374(8):738–748.

119. Cancer Stat Facts: Vulvar Cancer. Available online: <https://seer.cancer.gov/statfacts/html/vulva.html> (accessed on august 2023).
120. Global Cancer Observatory—Estimated Number of New Cases in 2020, Vulva, Females, All Ages. Available online: https://gco.iarc.fr/today/online-analysis-pie?v=2020&mode=population&mode_population=income&population=900&populations=900&key=total&sex=2&cancer=21&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=7&group_cancer=1&include_nmssc=0&include_nmssc_other=1&half_pie=0&donut=0 (accessed on august 2023). 3.
121. Global Cancer Observatory—Estimated Number of Deaths in 2020, Vulva, Female, All Ages. Available online: https://gco.iarc.fr/today/online-analysis-pie?v=2020&mode=population&mode_population=income&population=900&populations=900&key=total&sex=2&cancer=21&type=1&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=7&group_cancer=1&include_nmssc=0&include_nmssc_other=1&half_pie=0&donut=0 (accessed on august 2023).
122. Vulvar Cancer Treatment (PDQ®)—Health Professional Version. Available online: https://www.cancer.gov/types/vulvar/hp/vulvar-treatment-pdq#section/_1 (accessed on august 2023).
123. Figge, D.C. Rare vulvar malignancies. *J. Curr. Top. Obstet. Gynecol.* 1991, 239, 257.
124. Butt, J.L.; Botha, M.H. Vulvar cancer is not a disease of the elderly: Treatment and outcome at a tertiary referral centre in South Africa. *S. Afr. Med. J.* 2017, 107, 1000–1004.
125. Kang, Y.J.; Smith, M.; Barlow, E.; Coffey, K.; Hacker, N.; Canfell, K. Vulvar cancer in high-income countries: Increasing burden of disease. *Int. J. Cancer* 2017, 141, 2174–2186.
126. Forman, D.; de Martel, C.; Lacey, C.J.; Soerjomataram, I.; Lortet-Tieulent, J.; Bruni, L.; Vignat, J.; Ferlay, J.; Bray, F.; Plummer, M.; et al. Global burden of human papillomavirus and related diseases. *Vaccine* 2012, 30 (Suppl. S5), F12–F23.
127. Allbritton, J.I. Vulvar Neoplasms, Benign and Malignant. *Obstet. Gynecol. Clin. N. Am.* 2017, 44, 339–352.
128. Xiao, X.; Meng, Y.B.; Bai, P.; Zou, J.; Zhang, Y.; Nguyen, T.M.B.; Xiao, J.G.; Gao, X.M.; Wen, B.F. Vulvar Cancer in China: Epidemiological Features and Risk Analysis. *J. Cancer* 2017, 8, 2950–2958.
129. Hampl, M.; Sarajuuri, H.; Wentzensen, N.; Bender, H.G.; Kueppers, V. Effect of human papillomavirus vaccines on vulvar, vaginal, and anal intraepithelial lesions and vulvar cancer. *Obstet. Gynecol.* 2006, 108, 1361–1368.
130. Serrano, B.; de Sanjose, S.; Tous, S.; Quiros, B.; Munoz, N.; Bosch, X.; Alemany, L. Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions. *Eur. J. Cancer* 2015, 51, 1732–1741.
131. Joura, E.A.; Leodolter, S.; Hernandez-Avila, M.; Wheeler, C.M.; Perez, G.; Koutsky, L.A.; Garland, S.M.; Harper, D.M.; Tang, G.W.; Ferris, D.G.; et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: A combined analysis of three randomised clinical trials. *Lancet* 2007, 369, 1693–1702.
132. Pils, S.; Gensthaler, L.; Alemany, L.; Horvat, R.; de Sanjose, S.; Joura, E.A. HPV prevalence in vulvar cancer in Austria. *Wien. Klin. Wochenschr.* 2017, 129, 805–809.
133. Olawaiye, A.B.; Cuello, M.A.; Rogers, L.J. Cancer of the vulva: 2021 update. *Int. J. Gynaecol. Obstet.* 2021, 155 (Suppl. S1), 7–18.
134. Schmitt, A.R.; Long, B.J.; Weaver, A.L.; McGree, M.E.; Bakkum-Gamez, J.N.; Brewer, J.D.; Cliby, W.A. Evidence-Based Screening Recommendations for Occult Cancers in the Setting of

- Newly Diagnosed Extramammary Paget Disease. *Mayo Clin. Proc.* 2018, 93, 877–883.
135. Lin, G.; Chen, C.Y.; Liu, F.Y.; Yang, L.Y.; Huang, H.J.; Huang, Y.T.; Jung, S.M.; Chou, H.H.; Lai, C.H.; Ng, K.K. Computed tomography, magnetic resonance imaging and FDG positron emission tomography in the management of vulvar malignancies. *Eur. Radiol.* 2015, 25, 1267–1278.
136. Shetty, A.S.; Menias, C.O. MR Imaging of Vulvar and Vaginal Cancer. *Magn. Reson. Imaging Clin.* 2017, 25, 481–502.
137. van den Einden, L.C.; Massuger, L.F.; Jonkman, J.K.; Bult, P.; de Hullu, J.A.; Bulten, J. An alternative way to measure the depth of invasion of vulvar squamous cell carcinoma in relation to prognosis. *Mod. Pathol.* 2015, 28, 295–302.
138. Skala, S.L.; Ebbott, J.A.; Zhao, L.; Lieberman, R.W. Predictive Value of an Alternative Strategy for Measuring Depth and Size of Stage 1 Vulvar Squamous Cell Carcinoma. *J. Low Genit. Tract Dis.* 2020, 24, 265–271.
139. Hacker, N.F.; Barlow, E.L. Staging for vulvar cancer. *Best Pract. Res. Clin. Obstet. Gynaecol.* 2015, 29, 802–811.
140. Andersen, B.L.; Hacker, N.F. Psychosexual adjustment after vulvar surgery. *Obstet. Gynecol.* 1983, 62, 457–462.
141. de Hullu, J.A.; van der Zee, A.G. Surgery and radiotherapy in vulvar cancer. *Crit. Rev. Oncol. Hematol.* 2006, 60, 38–58. [CrossRef] [PubMed]
63. Podratz, K.C.; Symmonds, R.E.; Taylor, W.F.; Williams, T.J. Carcinoma of the vulva: Analysis of treatment and survival. *Obstet. Gynecol.* 1983, 61, 63–74. *Cancers* 2022, 14, 4184 20 of 24
142. Carlson, J.W.; Kauderer, J.; Walker, J.L.; Gold, M.A.; O'Malley, D.; Tuller, E.; Clarke-Pearson, D.L.; Gynecologic Oncology, G. A randomized phase III trial of VH fibrin sealant to reduce lymphedema after inguinal lymph node dissection: A Gynecologic Oncology Group study. *Gynecol. Oncol.* 2008, 110, 76–82.
143. DiSaia, P.J.; Creasman, W.T.; Rich, W.M. An alternate approach to early cancer of the vulva. *Am. J. Obstet. Gynecol.* 1979, 133, 825–832.
144. Hacker, N.F.; Berek, J.S.; Lagasse, L.D.; Nieberg, R.K.; Leuchter, R.S. Individualization of treatment for stage I squamous cell vulvar carcinoma. *Obstet. Gynecol.* 1984, 63, 155–162.
145. Braakhuis, B.J.; Tabor, M.P.; Kummer, J.A.; Leemans, C.R.; Brakenhoff, R.H. A genetic explanation of Slaughter's concept of field cancerization: Evidence and clinical implications. *Cancer Res.* 2003, 63, 1727–1730.
146. . Ansink, A.; van der Velden, J. Surgical interventions for early squamous cell carcinoma of the vulva. *Cochrane Database Syst. Rev.* 2000, 2, CD002036.
147. De Hullu, J.A.; Hollema, H.; Lolkema, S.; Boezen, M.; Boonstra, H.; Burger, M.P.; Aalders, J.G.; Mourits, M.J.; Van Der Zee, A.G. Vulvar carcinoma. The price of less radical surgery. *Cancer* 2002, 95, 2331–2338.
148. Berek, J.S.; Hacker, N.F. *Berek & Hacker's Gynecologic Oncology*, 7th ed.; Wolters Kluwer: Alphen aan den Rijn, The Netherlands, 2015.
149. Frey, J.N.; Hampl, M.; Mueller, M.D.; Gunthert, A.R. Should Groin Recurrence Still Be Considered as a Palliative Situation in Vulvar Cancer Patients?: A Brief Report. *Int. J. Gynecol. Cancer* 2016, 26, 575–579.
150. Bhatla, N.; Tomar, S.; Meena, J.; Sharma, D.N.; Kumar, L. Adjuvant treatment in cervical, vaginal and vulvar cancer. *Best Pract. Res. Clin. Obstet. Gynaecol.* 2022, 78, 36–51.
151. Oonk, M.H.M.; Slomovitz, B.; Baldwin, P.J.W.; van Doorn, H.C.; van der Velden, J.; de Hullu, J.A.; Gaarenstroom, K.N.; Slangen, B.F.M.; Vergote, I.; Brannstrom, M.; et al. Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II. *J. Clin. Oncol.* 2021, 39, 3623–3632.

152. Gill, B.S.; Bernard, M.E.; Lin, J.F.; Balasubramani, G.K.; Rajagopalan, M.S.; Sukumvanich, P.; Krivak, T.C.; Olawaiye, A.B.; Kelley, J.L.; Beriwal, S. Impact of adjuvant chemotherapy with radiation for node-positive vulvar cancer: A National Cancer Data Base (NCDB) analysis. *Gynecol. Oncol.* 2015, 137, 365–372.
153. Mahner, S.; Jueckstock, J.; Hilpert, F.; Neuser, P.; Harter, P.; de Gregorio, N.; Hasenburger, A.; Sehouli, J.; Habermann, A.; Hillemanns, P.; et al. Adjuvant therapy in lymph node-positive vulvar cancer: The AGO-CaRE-1 study. *J. Natl. Cancer. Inst.* 2015, 107, dju426.
154. Aalders J, Abeler V. Recurrent Adenocarcinoma of the Endometrium: A Clinical and Histopathological Study of 379 Patients. *Oncology* (1984).
155. CCE. *AJCC Cancer Staging Manual*. Japan: Springer (2010).
156. 3. Curran J, Whittington R. Vaginal Recurrences of Endometrial Carcinoma: The Prognostic Value of Staging by a Primary Vaginal Carcinoma System. (1988).
157. Dancuart F, Delclos L, Wharton J. Primary Squamous Cell Carcinoma of the Vagina Treated by Radiotherapy: A Failures Analysis—the MD Anderson Hospital Experience 1955–1982. (1988).
158. Viswanathan AN, Erickson BE, Rownd J. Image-Based Approaches to Interstitial Brachytherapy. Berlin, Heidelberg: *Gynecol. Radiat. Ther.* Springer Berlin Heidelberg (2011) p. pp 247–59.
159. Perez CA, Grigsby PW, Garipagaoglu M, Mutch DG, Lockett MA. Factors Affecting Long-Term Outcome of Irradiation in Carcinoma of the Vagina. *Int J Radiat Oncol* (1999) 44:37–45
160. Brinton LA, Nasca PC, Mallin K, Schairer C, Rosenthal J, Rothenberg R, et al. Case-Control Study of in Situ and Invasive Carcinoma of the Vagina. *Gynecol Oncol* (1990) 38:49–54.
161. Parkin DM, Bray F, Ferlay J, Pisani P. Global Cancer Statistics, 2002. *CA Cancer J Clin* (2005) 55:74–108.
162. Di Donato V, Bellati F, Fischetti M, Plotti F, Perniola G, Benedetti Panici P. Vaginal Cancer. *Crit Rev Oncol Hematol* (2012) 81:286–95.
163. Grigsby PW. Vaginal Cancer. *Curr Treat Options Oncol* (2002) 3:125–30
164. Bacalbasa N. Therapeutic Strategies in Primary Malignancies of the Vagina— a Literature Review. *Rom J Med Pract* (2015).
165. Carter JS, Downs LS. Vulvar and Vaginal Cancer. *Obstet Gynecol Clin North Am* (2012) 39:213–31.
166. Siegel R, Ma J, Zou Z, Jemal A. *Cancer Statistics, 2014*. *CA Cancer J Clin* (2014) 64:9–29.
167. Rajaram S, Maheshwari A, Srivastava A. Staging for Vaginal Cancer. *Best Pract Res Clin Obstet Gynaecol* (2015) 29:822–32.
168. Sugarbaker PH. Observations Concerning Cancer Spread Within the Peritoneal Cavity and Concepts Supporting an Ordered Pathophysiology. *Cancer Treat Res* (1996) 82:79–100.
169. Okamura H, Cytol HK-IR. Pathophysiological Dynamics of Human Ovarian Surface Epithelial Cells in Epithelial Ovarian Carcinogenesis. *Int Rev Cytol* (2005) 242:1–54.
170. Frank SJ, Deavers MT, Jhingran A, Bodurka DC, Eifel PJ. Primary Adenocarcinoma of the Vagina Not Associated With Diethylstilbestrol (DES) Exposure. *Gynecol Oncol* (2007) 105:470–4.
171. Beller U, Benedet J, Creasman W, Ngan H, Quinn M, Maisonneuve Pecorelli S, et al. Carcinoma of the Vagina. *Int J Gynecol Obstet* (2006) 95:S29–42.
172. Ratnavelu N, Patel A, Fisher A, Galaal K, Cross P, Naik R. High-Grade Vaginal Intraepithelial Neoplasia: Can We be Selective About Who We Treat? *BJOG Int J Obstet Gynaecol* (2013) 120:887–93.
173. Gunderson CC, Nugent EK, Elfrink SH, Gold MA, Moore KN. A Contemporary Analysis of Epidemiology and Management of Vaginal Intraepithelial Neoplasia. *Am J Obstet Gynecol* (2013) 208:410.e1–6.
174. Liao JB, Jean S, Wilkinson-Ryan I, Ford AE, Tanyi JL, Hagemann AR, et al. Vaginal Intraepithelial

- Neoplasia (VAIN) After Radiation Therapy for Gynecologic Malignancies: A Clinically Recalcitrant Entity. *Gynecol Oncol* (2011) 120:108–12.
175. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global Cancer Statistics, 2012. *CA Cancer J Clin* (2015) 65:87–108.
176. Duong TH, Flowers LC. Vulvo-Vaginal Cancers: Risks, Evaluation, Prevention and Early Detection. *Obstet Gynecol Clin North Am* (2007) 34:783–802
177. Mittendorf R. Teratogen Update: Carcinogenesis and Teratogenesis Associated With Exposure to Diethylstilbestrol (DES) In Utero. *Teratology* (1995) 51:435–45.
178. Mehasseb MK. Vaginal Cancer. *Clin Gynecol* (2015), 736–43.
179. Palmer J, Anderson D, Helmrich S. Risk Factors for Diethylstilbestrol Associated Clear Cell Adenocarcinoma. *Gynecology* (2000).
180. HF II, Jacox H. Primary Carcinoma of the Vagina. *Gynecology* (1968).
181. Frank SJ, Jhingran A, Levenback C, Eifel PJ. Definitive Radiation Therapy for Squamous Cell Carcinoma of the Vagina. *Int J Radiat Oncol* (2005) 62:138–47.
182. Perez CA, Camel HM, Galakatos AE, Grigsby PW, Kuske RR, Buchsbaum G, et al. Definitive Irradiation in Carcinoma of the Vagina: Long-Term Evaluation of Results. *Int J Radiat Oncol* (1988) 15:1283–90.
183. Tran PT, Su Z, Lee P, Lavori P, Husain A, Teng N, et al. Prognostic Factors for Outcomes and Complications for Primary Squamous Cell Carcinoma of the Vagina Treated With Radiation. *Gynecol Oncol* (2007) 105:641–9.
184. Chyle V, Zagars GK, Wheeler JA, Wharton JT, Delclos L. Definitive Radiotherapy for Carcinoma of the Vagina: Outcome and Prognostic Factors. *Int J Radiat Oncol* (1996) 35:891–905.
185. Lian J, Dundas G, Carlone M, Ghosh S, Pearcey R. Twenty-Year Review of Radiotherapy for Vaginal Cancer: An Institutional Experience. *Gynecol Oncol* (2008) 111:298–306.
186. Dalrymple JL, Russell AH, Lee SW, Scudder SA, Leiserowitz GS, Kinney WK, et al. Chemoradiation for Primary Invasive Squamous Carcinoma of the Vagina. *Int J Gynecol Cancer* (2004) 14:110–7.
187. Samant R, Lau B EC, Le T, Tam T. Primary Vaginal Cancer Treated With Concurrent Chemoradiation Using Cis-Platinum. *Int J Radiat Oncol* (2007) 69:746–50.
188. Stock RG, Chen ASJ, Seski J. A 30-Year Experience in the Management of Primary Carcinoma of the Vagina: Analysis of Prognostic Factors and Treatment Modalities. *Gynecol Oncol* (1995) 56:45–52.
189. Ball HG, Berman ML. Management of Primary Vaginal Carcinoma. *Gynecol Oncol* (1982) 14:154–63.
190. Tjalma WAA, Monaghan JM, de Barros Lopes A, Naik R, Nordin AJ, Weyler JJ. The Role of Surgery in Invasive Squamous Carcinoma of the Vagina. *Gynecol Oncol* (2001) 81:360–5.
191. Davis KP, Stanhope CR, Garton GR, Atkinson EJ, O'Brien PC. Invasive Vaginal Carcinoma: Analysis of Early-Stage Disease. *Gynecol Oncol* (1991) 42:131–6.
192. Creasman W. The National Cancer Data Base Report on Cancer of the Vagina. *Cancer: Interdisciplinary International Journal of the American Cancer Society* (1998) 83:1033–1040.
193. Chu AM, Beechinor R. Survival and Recurrence Patterns in the Radiation Treatment of Carcinoma of the Vagina. *Gynecol Oncol* (1984) 19:298–307.
194. Dixit S, Singhal S, Baboo HA. Squamous Cell Carcinoma of the Vagina: A Review of 70 Cases. *Gynecol Oncol* (1993) 48:80–7.
195. Leung S, Sexton M. Radical Radiation Therapy for Carcinoma of the Vagina —Impact of Treatment Modalities on Outcome: Peter MacCallum

- Cancer Institute Experience 1970–1990. *Int J Radiat Oncol* (1993) 25:413–8.
196. Dunn LJ, Napier JG. Primary Carcinoma of the Vagina. *Am J Obstet Gynecol* (1966) 96:1112–6.
197. Lee WR, Marcus RB, Sombeck MD, Mendenhall WM, Morgan LS, Freeman DE, et al. Radiotherapy Alone for Carcinoma of the Vagina: The Importance of Overall Treatment Time. *Int J Radiat Oncol* (1994) 29:983–8.
198. Tewari KS, Cappuccini F, Puthawala AA, Kuo JV, Burger RA, Monk BJ, et al. Primary Invasive Carcinoma of the Vagina. *Cancer* (2001) 91:758–70.
199. Kucera H, Vavra N. Radiation Management of Primary Carcinoma of the Vagina: Clinical and Histopathological Variables Associated With Survival. *Gynecol Oncol* (1991) 40:12–6.
200. Benedet J, Murphy K. Primary Invasive Carcinoma of the Vagina. *Gynecology* (1983). 105. Kersh C, Constable W, Spaulding C, Cancer S-. A Phase I-II Trial of Multimodality Management of Bulky Gynecologic Malignancy: Combined Chemoradiosensitization and Radiotherapy. *Cancer* (1990) 66:30–34.
201. Kunos CA, Radivoyevitch T, Waggoner S, et al. Radiochemotherapy Plus 3- Aminopyridine-2- Carboxaldehyde Thiosemicarbazone (3-AP, NSC #663249) in Advanced-Stage Cervical and Vaginal Cancers. *Gynecol Oncol* (2013) 130:75–80.
202. 108. St. Laurent J, Lockett R, Feldman S. HPV Vaccination and the Effects on Rates of HPV-Related Cancers. *Curr Probl Cancer* (2018) 42:493–506.
203. Zur Hausen H, de Villiers E-M. Reprint of: Cancer “Causation” by Infections—Individual Contributions and Synergistic Networks. *Semin Oncol* (2015) 42:207–22.
204. Winer RL, Koutsky LA. The Epidemiology of Human Papillomavirus Infections. *Cancer Prevention — Cancer Causes book series (CPCC, volume 2)* (2004) 143–87.
205. Herrero R, González P. Present Status of Human Papillomavirus Vaccine Development and Implementation. *Oncology* (2015) 16:e206–16.
206. Lowy D, Herrero R. Primary Endpoints for Future Prophylactic Human Papillomavirus Vaccine Trials: Towards Infection and Immunobridging. *Oncology* (2015).
207. Herzog T. The Impact of Cervical Cancer on Quality of Life—the Components and Means for Management. *oncology* (2007).
208. Edwards JNT, Morris HB. Langerhans’ Cells and Lymphocyte Subsets in the Female Genital Tract. *BJOG Int J Obstet Gynaecol* (1985) 92:974–82.
209. Li HD, Liang YZ, Xu QS, Cao DS, Tan BB, Deng BC, Lin CC. Recipe for uncovering predictive genes using support vector machines based on model population analysis. *IEEE/ACM Transactions on Computational Biology and Bioinformatics*. 2011, 8(6):1633-1641.
210. Hu Q, Pan W, An S, Ma P, Wei J. An efficient gene selection technique for cancer recognition based on neighborhood mutual information. *International Journal of Machine Learning and Cybernetics*. 2010, 1(1-4):63-74.
211. Skov M, Hansen C, Pressler T. Cystic fibrosis - An example of personalized and precision medicine. *APMIS*. 2019, 127(5):352-360.
212. Yanase J, Triantaphyllou E. A systematic survey of computer-aided diagnosis in medicine: Past and present developments. *Expert Systems with Applications*. 2019, 138:112821